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ABSTRACT 
PSYCHOMETRIC PROPERTIES OF THE MINNESOTA MULTIPHASIC 
PERSONALITY INVENTORY-2-RESTRUCTURED FORM (MMPI-2-RF) FBS-r, Fs, 
and RBS SCALES IN A NEUROPSYCHOLOGICAL SETTING 
Danielle M. Eason Ransom 
Old Dominion University, 2012 
Director: Dr. Richard Handel 
The Minnesota Multiphasic Personality Inventory-2 (MMPI-2) is the most widely 
used self-report measure of personality and psychopathology in the United States. The 
recently released MMPI-2-RF (Restructured Form), meanwhile, was designed to be a 
shorter and more efficient version of the MMPI-2. All MMPI-2-RF items are fully 
contained within the larger MMPI-2 and all MMPI-2-RF scales may be scored from a 
standard MMPI-2 administration. This study sought to examine the relationship between 
the RBS, Fs, and FBS-r over-reporting validity scales of the MMPI-2-RF, a stand-alone 
measure of symptom validity/cognitive effort, and neuropsychological indicators 
commonly used in assessment batteries. Results of this study supported the clinical 
utility of the RBS, FBS-r, and Fs, though RBS demonstrated superior predictive utility by 
explaining performance above and beyond FBS-r and Fs. Since the assessment of 
symptom exaggeration should be a multifactorial approach, incorporating these 
embedded measures of validity may provide additional information for 
neuropsychological assessments. 
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The objectives of this study are two-fold. The first objective is to examine the 
relationship between specific over-reporting validity scales of the Minnesota Multiphasic 
Personality Inventory-2-Restructured Form (MMPI-2-RF), chosen measures of symptom 
validity, and neuropsychological performance indicators commonly used in assessment 
batteries. The second objective is to shed light on the utility of the MMPI-2-RF as 
additional assessment of symptom validity in an assessment battery. 
Neuropsychological assessments are subject to intensive speculation of specificity 
and sensitivity in detecting dysfunction; however, these measures rely upon each 
patient's motivation and effort during the testing battery (Cullum, Heaton, & Grant, 
1991). If motivation and effort are poor, then test scores falling below the average range 
may not be indicative of impaired brain functions (Cullum et al., 1991). Demakis, Sweet, 
Sawyer, Moulthrop, Nies, and Clingerman (2001) stated, "If effort is fully applied 
throughout testing, the resulting test data can be considered valid, but if incompletely or 
insufficiently applied (whether because of psychopathology, malingering, or some other 
cause), test data may be invalid (240)." 
Invalid test data may result from, but is not limited to, symptom exaggeration, 
sometimes referred to as over-reporting. As noted by Ben-Porath and Tellegen (2008), 
over-reporting is not synonymous with malingering. Test-takers may over-report 
symptoms for a variety of reasons, which may include malingering, but there are other 
possible explanations (e.g., somatoform disorder). Ben-Porath and Tellegen (2008) 
stressed that extra-test data (e.g., clinical interview) are needed to rule-in or rule-out 
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malingering. Nevertheless, psychological test data can be a useful component in the 
overall assessment of malingering. 
Malingering is a medical term referring to the fabrication of either physical or 
medical symptoms due to external incentives that may include financial compensation, 
avoiding school, work, or military service, obtaining drugs, reducing a criminal sentence, 
or to gain attention or sympathy (Rogers, 2008). Zillmer and Green (2006) stated that 
there are many reasons for invalid or biased performance and malingering may only be 
one of these reasons. Causes may range from definite malingering and volitional 
distortion of performance to more subtle nuances, including exaggeration or even 
neurologic symptoms (Zillmer & Green, 2006). 
Resnick (1997) described three types of malingering, which he labeled "pure 
malingering," involving a complete fabrication of symptoms; "partial malingering," 
defined as the exaggeration of actual symptoms or by reporting the false continuation of 
past symptoms; and "false imputation," referring to the deliberate misattribution of actual 
symptoms to the event. It is important for neuropsychologists to move away from the 
dichotomous classification system where only pure malingering is considered, as effort 
falls on a continuum from very poor to outstanding (Iverson, 2006). Recent research 
indicates that general malingering constitutes a large portion of response bias; therefore, 
neuropsychologists must have expertise in the evaluation of one's test-taking approach 
and their exerted effort to make a determination regarding underlying effort and 
motivation to perform (Zillmer & Green, 2006; Iverson, 2006). 
Failure to detect cases of malingering imposes a substantial economic burden on 
the health care system in the United States; conversely, false attribution of malingering 
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imposes a substantial burden of suffering on a significant portion of the patient 
population (Garriga, 2007). Survey data indicate that 20-40% of compensation-seeking 
adults are thought to be feigning some type of neuropsychological impairment 
(Mittenberg, Patton, Canyock, & Condit, 2001). The costs to the health care system and 
society in general are measurable in terms of dollars, safety, and availability of health 
care (Garriga, 2007). In 2006, the Texas Department of Insurance estimated that fraud, 
including malingering, costs the insurance industry an annual sum of $150 billion, which 
subsequently increases the cost of insurance by $1800 per family on average. Costs to 
public safety are inflicted when bottlenecking occurs in the criminal courts and when 
psychiatric inpatient beds are full and admission is deferred (Garriga, 2007). When 
malingering is not considered in clinical practice, those truly ill patients are frequently 
delayed or denied care (Garriga, 2007). 
In neuropsychology, assessment of symptom validity is crucial to maximize 
confidence in the results obtained from neurocognitive and personality measures and in 
the diagnoses and recommendations based upon these results (Bush, Ruff, Troster, Barth, 
Koffler, Pliskin, Reynolds, & Silver, 2005). Clinicians must take caution when basing 
conclusions about response style and effort on one measure, as doing so requires the 
clinician to infer that similar response styles and effort were employed by the examinee 
when completing all measures (Otto, 2008). Therefore, a complete assessment should 
include tests of symptom validity, in addition to evaluating the consistency across test 
results and the patient's self-report, cultural factors, the pattern of test results, and 
demand characteristics of the testing situation (Zillmer & Green, 2006). It has been found 
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that unless specific measures of malingering are used, many malingerers go without 
detection (Rogers, 1998). 
Individuals with and without brain dysfunction may complain of diminished 
abilities; subsequently, it is standard practice for neuropsychologists to assess for effort 
and symptom exaggeration. If a clinician is making inferences from performance 
instruments, it is especially crucial to evaluate effort, as sufficient output must be exerted 
by the examinee on all tests of ability to ensure valid results (Heilbronner, Sweet, 
Morgan, Larrabee, Millis, and Conference Participants, 2009). Therefore, effort should be 
evaluated repeatedly, if not continuously, throughout the course of an examination 
(Boone, 2009). These measures may take the form of stand-alone cognitive effort tests, 
embedded indicators within ability tests, and evaluation of response bias within disorder-
specific and personality inventories. The recommendations of the American Academy of 
Clinical Neuropsychology (AACN, 2009) state, "Stand-alone effort measures and 
embedded validity indicators should both be employed" and "When a psychological 
disorder (e.g., depression) and ability deficits (e.g., memory) are claimed, clinicians 
should administer measures that can evaluate response bias related to both." 
In choosing tests for any given battery, neuropsychologists select assessments 
with broad, empirical foundations to enhance the accuracy of the conclusions drawn and 
the usefulness of the information gleaned (Iverson, 2006). The same psychometric 
standards must be applied to the assessment of effort. Both traditional and specialized 
measures have been developed to identify poor effort in neuropsychology (Iverson, 
2010). Traditional tests are those that have been developed to measure a specific ability 
and are also used to identify poor effort (Iverson, 2010). Examples include the California 
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Verbal Learning Test, the Category Test, Digit Span, Reliable Digit Span, Vocabulary-
Digit Span Difference Scores, the Rey Auditory Verbal Learning Test, the Recognition 
Memory Test, and the Wechsler Memory Scale—Third Edition. Specialized tests are 
those that have been designed and validated specifically for the purpose of detecting poor 
effort (Iverson, 2010). Examples of these tests include the Amsterdam Short-Term 
Memory Test, b Test, the Computerized Assessment of Response Bias, the Dot Counting 
Test, the Portland Digit Recognition Test, the Rey 15-Item Test, the Test of Memory 
Malingering, the 21-Item Test, the Validity Indicator Profile, the Victoria Symptom 
Validity Test, and the Word Memory Test. This research will utilize three widely used 
and empirically supported measures, including Green's Memory Complaints Inventory 
(Green's MCI), and Green's Medical Symptom Validity Test (Green's MSVT). The 
reliability and validity of scores on these measures will be discussed in detail. 
Other measures of symptom validity are embedded within measures assessing a 
variety of constructs. For the purpose of this research, we will remain within the domain 
of personality assessment, specifically the MMPI-2-RF. The original MMPI (MMPI; 
Hathaway & McKinley, 1943) and MMPI-2 (Butcher, Graham, Ben-Porath, Tellegen, 
Dahlstrom, & Kaemmer, 2001) are examples of well researched clinical measures of 
personality and psychopathology that also provide scales designed to measure over-
reporting (Sellbom & Ben-Porath, 2006). Furthermore, the MMPI-2 is one of the five 
most widely used instruments in the determination of response bias (Sharland & Gfellar, 
2007). The MMPI was once the most frequently used self-report inventory, while the 
MMPI-2 remains the most frequently investigated and utilized psychological test 
(Archer, Buffington-Vollum, Stredny, & Handel, 2006; Sellom & Ben-Porath, 2006; 
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Lubin, Larsen, & Matarazzo, 1984; Piotrowski & Keller, 1989; Camara, Nathan & 
Puente, 2000; Butcher & Rouse, 1996). In 2008, a revised version of the MMPI-2, the 
MMPI-2-Restructured Form (MMPI-2-RF; Ben-Porath & Tellegen, 2008), was 
published. 
The main objective of the MMPI-2-RF project was to develop a set of 
psychometrically adequate scales that represent the clinically meaningful information 
presented in the MMPI-2 item pool (Tellegen & Ben-Porath, 2008). Although Tellegen 
and Ben-Porath (2008) provided substantial data on the psychometric properties of scores 
on the MMPI-2-RF in a number of samples, the measure is still relatively new. Therefore, 
additional empirical data would be useful in further establishing the psychometric 
properties of this measure in a wide variety of samples and applications. Toward this end, 
the current study aims to measure the relationship between embedded validity indicators, 
stand-alone symptom validity measures, and general performance on an ability test. This 
study will incorporate data from patients assessed at a neuropsychology private practice. 
Results of this research have aimed to expand the understanding of the use of the MMPI-
2-RF as an additional tool measuring symptom validity in the practice of 
neuropsychology. Since invalid performance on the MMPI-2-RF or any other measure of 
personality and psychopathology does not permit conclusions to be drawn regarding 
effort on other neurocognitive testing or vice versa, it is important to explore the 
reliability and validity scores on any new measure (Bush et al., 2005). 
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Defining Malingering 
The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text 
Revision (DSM-IV-TR) describes the essential feature of malingering as the intentional 
production of false or intentionally exaggerated symptoms (American Psychiatric 
Association [DSM-IV-TR], 2000). It should be particularly suspected if any of the 
following circumstances are present: the patient is referred by an attorney under a 
medico-legal context; a marked discrepancy exists between the patient's claimed stress or 
disability and the results of testing; the patient does not readily cooperate during the 
clinical interview and assessment as well as with the prescribed treatment regimen; and 
lastly, Antisocial Personality Disorder is suspected (DSM-IV-TR, 2000). Malingering can 
be distinguished from other psychiatric disorders, including Factitious Disorder, 
Conversion Disorder, and other Somatoform Disorders because of the intentional 
production of symptoms and the presence of external incentives (Cullum et al., 1991). 
The neuropsychological literature has employed a variety of terms to describe 
invalid information or test data, based upon either the examinee's self-report or observed 
behavior [while others emphasize the reasoning behind the invalidity] (Bush et al., 2005). 
First, symptom validity refers to the accuracy of the patient's behavioral presentation, 
self-reported symptoms, or performance on neuropsychological measures (Bush et al., 
2005). Second, response bias denotes a purposeful attempt to deceive or mislead the 
examiner through inaccurate or incomplete response patterns or effort (Bush et al., 2005). 
Third, effort is one's investment in their own performance and is indicative of their true 
capacity; in other words, the patient's effort to perform well on given measures (Bush et 
al., 2005). Fourth, dissimulation describes the attempt to appear dissimilar from one's 
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true condition through the over- or under-representation of true symptoms (Bush et al., 
2005). For the purpose of this research, each of these terms will be utilized. 
Prevalence of Malingering 
Over reporting or feigning neurological symptoms may occur in a sizable 
minority of patients in a neuropsychological assessment setting, especially in contexts 
with obvious secondary gain from performance falling below normal limits (Bush et al., 
2005). The symptoms most commonly claimed for disability are associated with 
disorders including mild head injury, fibromyalgia, chronic fatigue syndrome, chronic 
pain, and major depressive disorder (Rogers, 2008; Mittenberg, Patton, Canyock, & 
Condit, 2002). A review of the literature conducted by Larrabee (2003) found a rate of 
40% in 1,363 patients seeking compensation for mild head injury claims in 11 published 
studies using objective diagnostic measures. These results replicate previous findings 
utilizing a variety of objective methods (Binder & Kelly, 1996; Green, Rohling, Lees-
Haley, & Allen, 2001; Grote et al., 2000; Millis, 1994; Rohling, 2000; Youngjohn, 
Burrows, & Erdal, 1995). 
Among those claiming disability due to fibromyalgia, chronic fatigue syndrome, 
or major depressive disorder, 25-30% performed in a range that may indicate symptom 
exaggeration on forced choice tests (Mittenberg et al., 2002; Gervais, Russell, Green, 
Allen, Ferrari, & Pieschl, 2001; Green et al., 2001; Van der Werf, Prins, Jongen, Van der 
Meer, & Bleigenberg, 2000). Furthermore, similar results have been found for 
approximately 40% of those disability claimants with chronic pain (Mittenberg et al., 
2002; Gervais, Green, Allen, & Iverson, 2001). Regardless of diagnosis, approximately 
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25-30% of those presenting within the context of personal injury litigation, worker's 
compensation, and disability claims are believed to have exaggerated their symptom 
presentation (Green et al., 2001; Lees-Haley, 1997). 
Symptom Validity Assessment Guidelines 
The field of psychology has a long history of evaluating deception and 
psychologists have subsequently gained particular expertise in psychometrics and test 
theory (Zillmer & Green, 2006). Neuropsychologists, in particular, must consider the 
possibility of feigned or exaggerated performance as an integral part of their 
interpretation of tests results (Cullum et al., 1991). Those in clinical practice should 
engage in adequate assessment of symptom validity so that they may make appropriate 
diagnoses and recommendations, which are typically based upon patients' performance 
on neurocognitive and personality measures (Bush et al., 2005). Although 
neuropsychologists typically evaluate patients in multiple contexts, it is crucial that they 
utilize instruments that can effectively determine the veracity of symptom presentation, 
especially in a forensic setting (Sellbom, Toomey, Wygant, Kucharski, & Duncan, 2010). 
As a result, it has become standard practice to assess symptom validity, and 
neuropsychologists have created tests designed to measure these constructs (Bush et al., 
2005; Heilbronner et al., 2009; Zillmer & Green, 2006). 
With that said, it should not be implied that one should use a single test in 
isolation to identify the presence of over-reporting, or any other disorder (Millis, 2008; 
Zillmer & Green, 2006; Iverson, 2006). Neuropsychologists should determine whether an 
individual examinee's failure of one symptom validity domain also applies to a test in 
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another domain (Zillmer & Green, 2006). Preliminary research has demonstrated that 
symptom validity measures of cognition (e.g. memory malingering) and personality 
assessment (e.g., MMPI-2 and MCMI-DI) are unique and do not represent a single 
domain of dissimulation (Greiffenstein, Baker, Gola, Donders, & Miller, 2002; Larrabee, 
2003; McCaffrey, O'Bryant, Ashendorf, & Fisher, 2003; Ruocco, 2005). This implies the 
difficulty in predicting cognitive malingering from psychiatric malingering and vice 
versa; similar results have also been shown for performance tests, thus supporting the 
practice of utilizing different measures for assessing neuropsychological and psychiatric 
malingering (Zillmer & Green, 2006). However, there is an overlap among different 
types of symptom exaggeration. 
The evaluation of malingering is complex and requires converging evidence from 
multiple sources. If an examinee is determined to have engaged in malingering, then the 
clinician has concluded that he or she is purposely exaggerating and underperforming on 
testing to increase the likelihood of obtaining an obvious external incentive (Iverson, 
2006; Bianchini, Greve, & Glynn, 2005; Slick, Sherman, & Iverson, 1999; Millis, 2008). 
To make this determination, the AACN Consensus Conference statement (2009) 
confirms that clinicians can diagnose malingering in some patients, though this does not 
imply that malingering is a mental illness or disorder; rather, it is a designation and a 
term used to describe intentional exaggeration. Through scientific inquiry, clinicians can 
differentiate intentionally exaggerated presentations (e.g., malingering and factitious 
disorder) from unintentionally exaggerated presentations (e.g., somatoform pain disorder, 
cogniform disorder) (Heilbronner et al., 2009). To establish which diagnosis, the AACN 
recommends that clinicians ". ..consider the context of the evaluation and overall 
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presentation of the examinee, including background information, history information 
gathered during interview, observations, neuropsychological tests, and measures of 
response bias" (Heilbronner et al., 2009, 1097-1098). 
Measuring Symptom Validity 
There are many styles of symptom validity tests measuring negative response 
bias, motivation, and effort. A significant portion of these tests are described as "forced-
choice," which presents two alternatives to the examinee. By providing a 50% probability 
of obtaining the correct answer by chance alone, statistics suggests that scores less than 
50% are improbable and indicate deliberate choice of the wrong response (Gervais, Ben-
Porath, Wygant, & Green, 2007). 
While this sounds like a feasible basis for interpretation, sensitivity is 
compromised as this level of performance rarely occurs (Gervais et al., 2007). 
Empirically based, above-chance norms have been developed based on the performance 
of patients with severe traumatic brain injury, dementia, or other objective neurocognitive 
impairment (Rogers, 2008). This is known as a "floor approach," since scores that fall 
below the established cutoffs are associated with symptom exaggeration (Gervais et al., 
2007). The floor approach provides increased sensitivity while maintaining a high level 
of specificity and allows clinicians to have more confidence in the data (Gervais et al., 
2007). 
While there are many steps in the process of determining symptom validity, it 
should be emphasized that data from symptom validity tests should be given substantially 
greater weight than subjective indicators of effort, including statements by the examinee 
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and examiner observations (Bush et al., 2005). This is largely due to the increasing 
amount of scientific evidence supporting the sensitivity and specificity of symptom 
validity tests above and beyond subjective assessment (Bush et al., 2005). When invalid 
performance occurs on symptom validity measures, doubt may be cast upon the validity 
of other measures. At this point, the examiner must consider performance on all 
assessments of symptom validity and neurocognitive performance in order to provide 
justification for interpretation (Bush et al., 2005). If an examinee scores slightly below 
the cut-off on one SVT, it may not justify a conclusion of biased responding and the 
examiner should then refer to the data from other indicators (Bust et al., 2005). However, 
if invalid performance is corroborated by other assessments, the examinee's performance 
on ability tests may be interpreted as a representation of his or her minimum level of 
ability (Bust et al., 2005). As stated previously, it is important to remember invalid 
performance on a personality assessment, such as the MMPI-2-RF, does not allow for 
generalizations to be made regarding the validity of neurocognitive tests, though it should 
certainly raise questions regarding the overall validity of the assessment batter (Bush et 
al., 2005). There is a need to establish the utility of both cognitive and psychiatric 
measures of symptom validity. 
Development and Review of the MMPI-2-RF 
The MMPI-2 has also dominated forensic psychological assessment and meets the 
criteria outlined in the U.S. Supreme Court decision in Daubert v. Merrell Dow 
Pharmaceuticals Inc. (1993), which ruled the following: 
Trial judges must determine the validity of inferences based on a scientific 
technique by considering whether (1) the technique can be and has been 
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tested empirically, (2) the technique has been subjected to peer review, 
(3), the error rates of the technique are known, (4) there are standards for 
applying the technique, and (5) the technique is generally accepted in the 
relevant scientific discipline. 
While this ruling provides a basis for interpretation of data obtained from 
empirically supported psychological assessment measures, it does not provide much 
support for innovations in the way of change and improvement as a result of scientific 
scrutiny (Sellbom & Ben-Porath, 2006). For example, when the Restructured Clinical 
(RC) Scales were introduced in 2003, they did not possess the broad and extensive 
research base needed to guide interpretation as the original Clinical Scales (Sellbom & 
Ben-Porath, 2006). Even though revisions and enhancement of scales offered significant 
improvement, the recommendations at the time were to use the RC Scales to refine 
interpretation of the Clinical Scales until the research based broadened (Sellbom & Ben-
Porath, 2006). 
As the research supporting the RC Scales substantially increased, the next step 
was to create a restructured version of the MMPI-2. The goal of the MMPI-2-RF was to 
extend the work that began with the RC Scales, such that the development of substantive 
scales would capture the clinically relevant content of the MMPI-2 item pool (MMPI-2-
RF; Ben-Porath & Tellegen, 2008). Furthermore, improvements in psychometric 
properties included reducing intercorrelations among scales and enhanced discriminant 
and convergent validity compared to the MMPI-2 (MMPI-2-RF; Ben-Porath & Tellegen, 
2008). Research has established the comparability of scores of the 338 items comprising 
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the MMPI-2-RF scales with the 567 items that make up the scales of the MMPI-2 
(Tellegen & Ben-Porath, 2008; Van Der Heijden, Eger, & Derksen, 2010). 
The MMPI-2-RF is comprised of 338 of the original 567 items of the MMPI-2 for 
a total of 42 substantive scales (Ben-Porath & Tellegen, 2008). These include the Higher-
Order Scales, RC Scales, Specific Problem Scales, Interest Scales, and revised versions 
of the Personality Psychopathology Five Scales (MMPI-2-RF; Ben-Porath & Tellegen, 
2008). The MMPI-2-RF also includes revised versions of eight MMPI-2 Validity Scales: 
VRIN-r (Variable Response Inconsistency), TRIN-r (True Response Inconsistency), F-r 
(Infrequent Responses), Fp-r (Infrequent Psychopathology Responses), FBS-r (Symptom 
Validity), L-r (Uncommon Virtues), and K-r (Adjustment Validity) (MMPI-2-RF; Ben-
Porath & Tellegen, 2008). In addition, the MMPI-2-RF contains two new validity scale, 
Fs (Infrequent Somatic Responses) and RBS (Response Bias Scale), that measure over-
reporting of somatic and cognitive symptoms, respectively (MMPI-2-RF; Ben-Porath & 
Tellegen, 2008). 
The MMPI-2-RF was also designed to be less time-consuming and burdensome 
for patients compared to the MMPI-2, as it consists of 338 items instead of the 567 
featured on the MMPI-2 (Ben-Porath & Tellegen, 2008). No new items were added and 
the standardization sample remains the same (Ben-Porath & Tellegen, 2008). To date, the 
MMPI-2-RF scales have been validated with numerous populations (e.g., psychiatric 
inpatients, psychiatric outpatients, medical patients, disability patients, criminal 
defendants, and college students) using various criterion measures (e.g., intake variables, 
psychiatric diagnoses, patient description form variables, mental status variables, and 
discharge medications, in addition to a variety of self-report measures) (Ben-Porath & 
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Tellegen, 2008). For the purpose of this research, the RBS, FBS and FBS-r, and F-s will 
now be discussed. 
The Response Bias Scale (RBS) 
To aid in the detection of cognitive response bias, Gervais, Ben-Porath, Wygant, 
& Green (2007) developed the Response Bias Scale (RBS), which has been correlated 
with symptom validity test failure and exaggerated cognitive complaints. This scale is 
conceptually different from FBS, which identifies post-injury exaggeration of emotional 
distress and minimization of pre-injury emotional or personality problems (Gervais, Ben-
Porath, Wygant, & Sellbom, 2010). The RBS is the only MMPI-2/MMPI-2-RF scale 
developed from an actual forensic disability sample (Gervais et al., 2010). RBS was 
developed through an empirical-keying method involving multiple regression analyses to 
identify a set of MMPI-2 items that were correlated with failure on the Word Memory 
Test (WMT; Green, 2003), the Computerized Assessment of Response Bias (Allen, 
Conder, Green, & Cox, 1997), and the Test of Memory Malingering (TOMM; 
Tombaugh, 1996) (Gervais, et al., 2007). 
Gervais et al. (2007) reported Cronbach's Alpha coefficient of .76 for RBS scores 
in both their development and cross-validation samples. Furthermore, scores on RBS 
demonstrated statistically significant incremental validity when scores on F were entered 
in the first block of a regression equation. Scores on RBS also showed evidence of 
incremental validity when scores on FBS were entered in the first block of a second 
regression equation. In a third equation, the inclusion of RBS scores did not add 
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statistically significant incremental variance above and beyond Fp scores (Block 2 AR2 = 
.02, p = .06). 
A study examining the utility of the RBS and other MMPI-2 over-reporting scales 
in predicting TOMM performance indicated that the RBS exhibited the largest effect size 
(d = .98) when distinguishing between groups who passed and failed the TOMM 
(Whitney, Davis, Shepard, & Herman, 2008). Moreover, scores on the RBS were found 
to better predict score elevations on Green's Memory Complaints Inventory (Green, 
2004) in comparison to scores on the other MMPI-2 over-reporting scales, whereas no 
correlation was found between scores on the RBS and the California Verbal Learning 
Test (CVLT, Delis, Kramer, Kaplan, & Ober, 1987), an objective assessment of verbal 
learning (Gervais, Ben-Porath, Wygant, & Green, 2008). These results indicated that 
RBS scores successfully detected exaggeration of subjective memory complaints 
(Gervais et al., 2008). Similar results were found in predicting symptom validity test 
performance with disability and criminal forensic samples, as scores on RBS 
outperformed scores on over-reporting scales of the MMPI-2 (Wygant, Sellbom, Gervais, 
Ben-Porath, Stafford, Freeman, & Heilbronner, 2010). Overall, the research supports the 
use of the RBS as an effective measure of general symptom exaggeration as well as in 
predicting failure on symptom validity tests in disability settings (Wygant et al., 2010). 
The FBS and FBS-r 
Though the MMPI-2 has been one of the most widely used instruments employed 
by neuropsychologists (Archer et al., 2006), it did not include validity scales specifically 
designed to assess cognitive symptom exaggeration until the addition of the Symptom 
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Validity Scale (FBS; Lees-Haley, English, & Glenn, 1991). The FBS, formerly known as 
the Fake Bad Scale, is standardly scored on the MMPI-2 and is generally accepted as a 
measure of symptom over-reporting in personal injury settings (Sharland & Gfeller, 
2007; Greffenstein, 2010; Dionysus, Denney, & Halfaker, 2010). It has also demonstrated 
sensitivity to exaggerated disability in those seeking benefits for neurological trauma and 
has been supported by more than 45 research studies (Greiffenstein, Fox, & Lees-Haley, 
2007). 
There has been significant debate as to what FBS measures, though the research 
demonstrates its usefulness in detecting somatic and cognitive over-reporting (Graham, 
2006). FBS has demonstrated sensitivity to illogical symptom histories (Greiffenstein, 
Baker, Gola, Donders, & Miller, 2002) and has accurately identified patients with mild 
head injuries exerting poor cognitive effort (Slick, Hopp, Strauss, & Spellacy, 1996; 
Ross, Millis, Krukowski, Putnam, & Adams, 2004). 
Several studies have shown the positive relationship among elevated FBS scores, 
symptom exaggeration, and malingered neurocognitive dysfunction (Larrabee, 1998, 
2003; Slick et al., 1999). Research has also demonstrated scores on FBS are sensitive to 
exaggerated emotional distress in personal injury settings (Crawford, Greene, Dupart, 
Bongar, & Childs, 2006; Lees-Haley et al., 1991), as well as among those exhibiting 
somatic malingering (Larrabee, 1998,2003) and suboptimal effort on cognitive symptom 
validity tests (Greffeinstein et al., 2002; Larrabee, 2003, Ross et al., 2004; Bianchini, 
Love, Brennan, & Heinly, 2006). Lees-Haley, English, and Glenn (1991) found that FBS 
correctly classified 24 of 25 patients malingering emotional distress in the context of 
personal injury, while 18 of 20 patients assessed as presenting with genuine injuries were 
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correctly classified when a cut-off of 20 was utilized. FBS is twice as likely to be 
elevated among individuals with mild traumatic brain injury seeking compensation in 
comparison to those not seeking compensation (Miller & Donders, 2001). 
Furthermore, FBS has demonstrated its superiority to other MMPI-2 validity 
scales in detecting malingering in neuropsychological settings (Larrabee, 1998; Larrabee, 
2003; Millis, Putnam, & Adams, 1995; Putnam, Millis, & Adams, 1998; Tsushima & 
Tsushima, 2001). A recent meta-analysis documented the incremental validity of FBS 
scores in comparison to other scores on MMPI-2 validity scales in discriminating over-
reporting and comparison groups, thus supporting the use of FBS within forensic settings 
(Nelson, Hoelzle Sweet, Arbisi & Demakis, 2010). This meta analysis updated the 
composite effect size of FBS (d = 0.95), thus demonstrating greater stability and ability to 
differentiate among individuals with traumatic brain injuries based on effort (Nelson et 
al., 2010). 
However, some controversy exists regarding the interpretation of elevated FBS 
scores. Specifically, the likelihood of false positives increases in the presence of 
confounding variables, such as intensity of head injury or preinjury psychiatric history 
(Martens, Donders, & Millis, 2001). Elevations in psychiatric settings may not be 
indicative of malingered neurocognitive dysfunction, thereby reducing the sensitivity and 
specificity of FBS in this setting (Rogers, Sewell, & Ustad, 1995). In addition, data exists 
suggesting FBS has poor internal consistency, a high rate of false-positive identification, 
and over-identified malingering in a personal injury context (Butcher, Arbisi, Atlis, & 
McNulty, 2003). The methodology of this research has been questioned, including the 
sample distribution as well as failure to control for the effects of malingering (Lees-Haley 
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& Fox, 2004). The literature states . .raw scores above 28 on the FBS are associated 
with a very low false positive rate, which is consistent with the false positive rate of other 
standard MMPI-2 validity scales" (Ben-Porath & Tellegen, 20082, page 1). Overall, FBS 
has demonstrated clear validity in forensic settings (Nelson et al., 2010). 
FBS was revised for the MMPI-2-RF (FBS-r), resulting in the FBS-r scale (Ben-
Porath & Tellegen, 2OO82). Scores on FBS-r have produced large effect sizes in 
discriminating between medical control and medical simulation over-reporting samples 
(Wygant, Ben-Porath, Arbisi, Berry, Freeman, & Heilbronner, 2009). In order to provide 
a less inferential label in addition to better description of the scale, the FBS was renamed 
as the Symptom Validity scale (FBS-r) (Ben-Porath, Tellegen, & Graham, 2008). It is 
comprised of 30 of the 43 items originally on the FBS scale and has been used widely by 
neuropsychologists to aid in the identifying patients presenting with non-credible 
symptoms in the context of civil litigation (Ben-Porath & Tellegen, 2008). Research on 
the FBS-r will be discussed below. 
The Infrequent Somatic Responses Scale (Fs) 
Many of the MMPI-2 validity scales, including FBS, were revised for use with the 
MMPI-2-RF; however, the Infrequent Somatic Responses (Fs) was first introduced on the 
MMPI-2-RF. The Fs consists of 16 items that are somatic in content and were endorsed 
by 25% or less of medical and chronic pain patients (Wygant, Ben-Porath, & Arbisi, 
2004). This scale was designed to detect individuals who are over-reporting somatic or 
cognitive complaints, as it consist of somatic items rarely endorsed by medical patients 
(Ben-Porath & Tellegen, 2008). 
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Wygant (2007) employed this scale in a variety of settings, including simulations, 
known-groups, and mental health samples. Significant elevations were found among 
those patients who failed cognitive symptom validity tests as well as those instructed to 
feign symptoms of head injury (Wygant, 2007). These results also showed less of a 
correlation with measures of genuine somatic complaints and mood psychopathology in 
comparison to other MMPI-2 validity scales, thus establishing its ability to detect 
symptom exaggeration (Wygant, 2007). In general, the addition of Fs on the MMPI-2-RF 
has shown a strong benefit in predicting response bias. 
MMPI-2-RF Validity Scale Research 
Since the MMPI-2-RF is a relatively new measure, relatively few studies outside 
of the data presented in Tellegen and Ben-Porath (2008) have been conducted. However, 
the findings of these additional studies provide empirical support for MMPI-2-RF over-
reporting scales in both clinical and forensic settings (Gervais et al., 2010; Larrabee, 
2008; Gervais, Sellbom, & Wygant, 2010; Burchett & Ben-Porath, 2010; Locke, Kirlin, 
Thomas, Osborne, Hurst, Drazkowski, Sirven, & Noe, 2010; Sellbom, Toomey, Wygant, 
Kucharski, & Duncan, 2010). A review of the available research to date on the MMPI-2-
RF validity scales will now be discussed. 
Gervais and colleagues (2010) explored the utility of the MMPI-2-RF over-
reporting scales and the RBS in assessing the validity of subjective memory complaints. 
The scores on RBS were found to be more strongly correlated with scores on the Memory 
Complaints Inventory (r = .63) in comparison to scores on MMPI-2-RF validity scales 
(Gervais et al., 2010). With that said, however, the scores on MMPI-2-RF validity scales 
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were more strongly correlated with scores on measures of symptom validity in 
comparison to the scales of the MMPI-2 (Pearson's r for Fs and FBS-r = .51 and .50, 
respectively). These findings suggest that the over-reporting validity scales of the MMPI-
2-RF are more sensitive to potentially exaggerated memory complaints than those of the 
MMPI-2 and support its use as a measure of psychopathology in a forensic context 
(Gervais et al., 2010). Furthermore, the RBS was found to provide an incremental 
contribution in predicting memory complaints above and beyond the scales of the MMPI-
2-RF (Gervais et al., 2010). Similar results were found by Larrabee (2008) who compared 
the diagnostic validity of the MMPI-2 scales, MMPI-2-RF validity scales, and the RBS to 
distinguish between civil litigants and nonmalingering patients with true neurological 
disorders (e.g. moderate to severe brain injury) and psychiatric illness. The FBS, RBS, 
and FBS-r were found to have the strongest effect sizes when discriminating groups (d = 
1.99,1.91, and 1.85, respectively). 
The MMPI-2-RF validity scales have also shown clinical utility in detecting over-
reporting in a criminal forensic setting (Sellbom et al., 2010; Wygant et al., 2007; 
Burchett & Ben-Porath, 2010). Using a known-groups design, Sellbom et al. (2010) 
compared scores on the MMPI-2-RF validity scales and the Structured Interview of 
Reported Symptoms (SIRS; Rogers, 1992). Results demonstrated that F-r and Fp-r best 
discriminated between malingered and nonmalingered groups determined by the SIRS, 
which was expected given previous data with criminal populations (Sellbom et al., 2010). 
Notably, the FBS-r and Fs were still associated with large effect sizes when 
differentiating between groups, indicating the utility of these scales in the criminal setting 
(Sellbom et al., 2010). Burchett and Ben-Porath (2010) examined the substantive scale 
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score validity to determine the effect of over-reporting on the MMPI-2-RF among one 
simulated group instructed to feign somatic complaints, a second group instructed to 
feign psychopathology, and a third group as a control who received standard instructions. 
While a majority of the control group scored within the average range, somatic feigners 
and those feigning psychopathology elevated a significant number of scales. These 
studies support the notion that individuals in forensic evaluation settings who may profit 
from appearing mentally ill tend to over-report a wide variety of symptoms, including 
psychopathology, cognitive complaints, and somatic problems (Sellbom et al., 2010; 
Wygant et al., 2007; Burchett & Ben-Porath, 2010). 
The MMPI-2-RF has also been compared to results of other personality 
instruments. Gervais, Sellbom, and Wygant (2010) compared the MMPI-2-RF validity 
scales and RBS to the Personality Assessment Inventory (PAI) in predicting performance 
on four different symptom validity tests, including the Word Memory Test (WMT), the 
Medical Symptom Validity Test (MSVT), the Test of Memory Malingering (TOMM) 
Trial 2, and the Non-Verbal Medical Symptom Validity Test (NV-MSVT). In general, 
higher scores on the MMPI-2-RF and PAI over-reporting validity scales were associated 
with failure on symptom validity tests. The RBS obtained larger effect sizes in 
comparison to the MMPI-2-RF and PAI validity scales, which replicated previous 
findings (Gervais et al., 2010). 
The MMPI-2-RF validity scales have also demonstrated utility in detecting 
symptom exaggeration in medico-legal settings. Wygant and colleagues (2009) 
examined scores on the MMPI-2-RF and symptom validity test results in both simulation 
and known-groups samples. Data were gathered from control sample with actual head 
23 
injuries were compared to a group instructed to simulate symptoms of a head injury 
(Wygant et al., 2009). Results supported the use of Fs and and F-r to discriminate 
between true symptomatology and over-reporting of somatic and emotional complaints 
among those presenting with sequelae of head injury (Wygant et al., 2009). In a medical 
simulation sample, MMPI-2-RF validity scales were significantly elevated among those 
instructed to feign symptoms, though effect sizes were largest for FBS-r, F-r, and Fs (d = 
2.31, 2.03, and 1.97, respectively) (Wygant et al., 2009). These results were corroborated 
in a personal injury/disability sample in which participants were grouped based on 
symptom validity test performance, which demonstrates the utility of these scales to 
identify cognitive bias when a patient fails multiple symptom validity tests (Larrabee, 
2008). The results of this study speak to the ability of these MMPI-2-RF scales to detect 
exaggerated somatic, neurocognitive, and emotional complaints that may be seen in 
medico-legal settings (Wygant et al., 2009). 
Locke and colleagues (2010) conducted research on the MMPI-2-RF on an 
epilepsy monitoring unit. This study compared the scores of four different groups: (1) 
those diagnosed with epilepsy only, (2) those with psychogenic nonepileptic seizures 
(NES), (3) those with both epileptiform activity and some events showing no EEG 
activity, and (4) an indeterminate group based on a nondiagnostic admission with no 
typical events recorded and no data indicative of epilepsy (Locke et al., 2010). Among 
the validity scales, those diagnosed with NES demonstrated the highest score elevations 
on Fs and FBS-r in comparison to those in the epilepsy group (Locke et al., 2010). Other 
elevations were noted on the RC Scales, the Somatic/Cognitive Scales, the Internalizing 
Scale, and the Externalizing Scale (Locke et al., 2010). Overall, these results indicate that 
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those with NES report an increased rate of somatic symptoms in comparison to those 
diagnosed with epilepsy (Locke et al., 2010). 
To date, the research generally supports the use of the MMPI-2-RF over-reporting 
scales in both clinical and forensic settings, although relatively few studies have been 
conducted. 
Statement of the Problem 
It is standard practice in a thorough and competent assessment to assess the 
validity of claimed symptoms and obtained test data, especially in instances where 
secondary gain or incentives could influence the clinical presentation (Gervais et al., 
2010). Systematic assessment of malingering requires that clinicians obtain data from the 
clinical interview, as well as from self-report measures with embedded indicators and 
symptom validity tests, stand-alone cognitive effort tests, embedded indicators within 
ability tests, and evaluation of response bias within disorder-specific and personality 
inventories (Slick et al., 1999; Bianchini et al., 2005). Because of the prevalence of 
symptom exaggeration in the field, the American Academy of Clinical Neuropsychology 
has called for ongoing research efforts that strive to improve the effectiveness of 
procedures used by neuropsychologists (Heilbronner et al., 2009). Formal assessment of 
cognitive effort and performance validity primarily takes place through the administration 
of cognitive symptom validity tests, though research has shown that these indicators may 
not provide evidence regarding other areas of potential malingering (Gervais et al., 2010). 
The MMPI-2-RF is a relatively new measure of personality and psychopathology 
that was introduced with the objective to provide a more reliable and valid assessment 
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measure in a condensed, less burdensome format. Additional empirical data would be 
useful in further evaluating the psychometric properties of various MMPI-2-RF scales, 
particularly in the area of detecting over-reporting and symptom exaggeration. 
Specifically, few studies have been conducted on the new validity scales of this measure, 
especially in relation to symptom validity tests. 
The proposed study will expand the knowledge base surrounding the efficacy and 
utility of the MMPI-2-RF in neuropsychological settings. By exploring the relationship 
among embedded validity indicators of the MMPI-2-RF, stand-alone symptom validity 
measures, and general performance on an ability test, new data will be gleaned regarding 
the use of the MMPI-2-RF in a clinical setting. The limitation of much past research on 
symptom exaggeration is the reliance on feigned symptom exaggeration; conversely, this 
study will incorporate the results from actual patients from a neuropsychology private 
practice. 
Invalid performance on the MMPI-2-RF or any other measure of personality 
raises questions regarding the reliability of assessment data (Bush et al., 2005). 
Therefore, it is important to explore the reliability and validity of this new measure. 
Results will further understanding of the use of the MMPI-2-RF as an additional tool 
measuring symptom validity in the practice of neuropsychology. The present study was 
undertaken to examine whether elevated scores on the RBS, the FBS-r, and Fs are 
associated with increased self-reported memory complaints, failure of one or more 
cognitive symptom validity tests, and poor performance on a measure of cognitive ability 




One hundred and fourteen patients were administered test batteries that included 
the MMPI-2, Green's Memory Complaints Inventory (MCI; Green, 2004), Green's 
Medical Symptom Validity Test (MSVT; Green, 2004), and the Repeatable Battery for 
the Assessment of Neuropsychological Status (RBANS; Randolph, 1998) from 2005 to 
2010. MMPI-2 data were then scored using MMPI-2-RF scales. Analyses excluded 
patients who omitted 15 or more MMPI-2-RF items or who obtained TRIN-r or VRIN-r 
T-scores greater than or equal to 80. After these exclusion criteria were applied, a total of 
77 patients produced valid profiles and were thus included in the analyses. This total 
sample size of 77 was less than originally projected; subsequently, this should be taken 
into consideration when interpreting findings. It should be noted that most participants 
included in this study were referred for neuropsychological evaluation to assess the 
potential presence of cognitive dysfunction, not to assess for the presence of psychiatric 
disorder. 
Archival data were collected from a private neuropsychology practice in Virginia 
Beach, VA. After cases were removed based on MMPI-2-RF criteria, the sample 
consisted of 77 English-speaking adults over the age of 18 (M = 44.39, SD = 12.81) who 
presented with cognitive complaints and were administered MMPI-2, MCI, MSVT, and 
RBANS as part of a larger clinical evaluation. Demographic information was gleaned 
from a record review and included age, gender, etiology of complaint, and highest 
education level attained. Across the sample, there were 36 males (41%) and 41 females 
included in the sample with a mean education level of 13.75 years (SD = 2.18). Of these 
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77 total participants, 53 (60%) were Caucasian, 15 (17%) were African American, and 9 
participants (9%) did not have ethnicity demarcated in their records. Nineteen patients 
(22%) were diagnosed with cognitive deficits secondary to a traumatic brain injury (TBI), 
22 (25%) were diagnosed with a mood disorder, eight (9%) were diagnosed with a pain-
related disorder, and two with substance abuse issues. Twenty-three participants (32%) 
reported a work-related injury, 23 participants (32%) reported a motor vehicle accident, 
15 participants (14%) complained of a significant history of mood-related disorders), 12 
(17%) presented with cognitive complaints as a result of a peripheral medical condition, 
and four participants (5%) reported a history of a progressive or degenerative neurologic 
condition. Participants were also identified on the basis of whether or not they were 
involved in some type of litigation (e.g., workers' compensation, disability, or personal 
injury) at the time of the evaluation. Specifically, 31 participants (40%) reported ongoing 
litigation at the time of evaluation while 46 participants denied active legal involvement. 
Instruments 
All participants in this study were administered a neuropsychological assessment 
battery consisting of a variety of cognitive tests, the MMPI-2, a number of symptom 
validity or effort tests, and self-report symptom questionnaires. For the purposes of the 
present study, the analyses focused on the MMPI-2-RF FBS-r and Fs scales, the RBS, the 
MCI, the MSVT, and the RBANS. 
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The MMPI-2-RF 
All participants were administered the MMPI-2; however, because all of the items 
of the MMPI-2-RF are included on the MMPI-2, it is possible to score MMPI-2-RF 
scales in archival MMPI-2 data sets. As previously stated, analyses have established the 
equivalence of scaled scores produced with the two versions of this instrument (Tellegen 
& Ben-Porath, 2008; Van Der Heijden, Eger, & Derksen, 2010). Extensive psychometric 
data on the MMPI-2-RF scales are available in Tellegen and Ben-Porath (2008). 
The RBS 
This 28 item MMPI-2 scale was developed to aid in the prediction of failed 
cognitive symptom validity tests. All items were retained in the MMPI-2-RF; the only 
changes were with respect to the numbering of the items (Gervais et al., 2010). Per 
Gervais et al. (2010), the scoring key and T-score conversion table for the RBS remains 
the same. 
Green's MCI 
The MCI is a computer-administered self-report inventory consisting of 58 items 
describing a variety of commonplace and implausible memory problems. The inventory 
has nine scales: General Memory Problems (GMP), Numeric Information Problems 
(NIP), Visuospatial Memory Problems (VSP), Verbal Memory Problems (VMP), Pain 
Interferes with Memory (PIM), Memory Interferes with Work (MIW), Impairment of 
Remote Memory (IRM), Amnesia for Complex Behavior (ACB), and Amnesia for 
Antisocial Behavior (AAB). Internal consistency was found to range from .79 to .93 in a 
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sample of 1550 consecutive non-head injury disability-related referrals. While the first 
six scales contain items describing the most plausible memory complaints, the last three 
scales describe the least credible memory problems that are rarely found in patients with 
organic memory impairment, but may be associated with psychological or psychiatric 
disorders (Gervais et al., 2008). In cases where secondary gain is involved, however, 
endorsement of these items may represent exaggerated or feigned memory complaints 
(Gervais et al., 2008). Individuals with moderate to severe traumatic brain injuries or 
neurological disorders who have passed the Word Memory Test report fewer memory 
complaints in comparison to patients diagnosed with mild brain injuries, chronic pain, 
anxiety, or depression that fail effort tests and complain about a greater number of 
memory impairments (Gervais et al., 2008). 
Green's MSVT 
The MSVT is a short, computerized, verbal memory screening test with various 
subtests that measure memory and response consistency (MSVT; Green, 2004). The test 
presents a list of 10 word pairs and then assesses recognition memory using a target-foil 
combination, which requires patients to identify the original word pairs amongst a list of 
novel words (Green, 2004). After a 10 minute delay, a similar recognition task is 
administered, followed by a paired associate trial, which is more difficult as the first word 
of each pair is presented and one's ability to recall the second word is assessed (Green, 
2004). Lastly, there is a free recall subtest (Green, 2004). 
Test takers receive 1 point, or 5%, for each correct word that is chosen from the 
original word list. Twenty words are presented in pairs and a test taker who chooses all 
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20 original words correctly would receive a score of 100%. A cutoff raw score of 85 
indicates that a test taker answered 85% of the items correctly. This score is two to three 
standard deviations below the mean of various clinical groups (e.g., children with ADHD, 
Fetal Alcohol Syndrome, psychiatric disorders) and normal adult volunteers, is suggested 
for immediate, delayed, and consistency indices, as performance at or below this score 
indicates a failure of the symptom validity subtests. In addition, cutoff raw scores of 70 
and 55 are suggested for the Paired Associate and Free Recall trials, respectively. The 
Consistency Index measures how consistent scores were from the Immediate Recall trial 
to the Delayed Recall trial (i.e., whether or not they were right or wrong on both trials). 
Research using this cutoff with a German-language version of the MSVT with 
simulated malingerers demonstrated 100% sensitivity and specificity between those 
feigning symptoms and the control group (Merten, Green, Henry, Blaskewitze, & 
Brockhaus, 2005). Overall, those simulating impairment have been shown to have very 
different profiles in comparison to those with actual neurocognitive symptomatology 
(Green, 2004). Individuals with genuine severe cognitive impairment can be 
distinguished from simulators by the presence of the "dementia" or "genuine memory 
impairment profile" (GMIP) in contrast to the "simulator" or "poor effort" profile (Howe 
& Loring, 2009). 
The RBANS 
The RBANS is a brief, individually administered neuropsychological screening 
tool that measures attention, language, visuospatial/constructional abilities, and 
immediate and delayed memory (Randolph, 1998). It consists of 12 subtests that yield 
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five Index scores and a Total Scale score (Randolph, 1998). The Attention Index is made 
up of a digit span task as well as a timed graphomotor coding task (Randolph, 1998). The 
Language Index requires the patient to name items presented in pictures and complete a 
task of semantic fluency (Randolph, 1998). The Visuospatial/Construction Index involves 
copying a complex figure and judging the orientation of lines (Randolph, 1998). The 
Immediate Memory Index measures the patient's ability to recall elements of a novel 
story and a list of unrelated words (Randolph, 1998). The Delayed Memory Index is 
based on four subtests, including delayed recall of the word list, story, and complex 
figure, as well as forced-choice recognition of the word list (Randolph, 1998). Normative 
information is based on 540 healthy adults ranging in age from 20-89 years and is 
presented in the manual to calculate the Index and Total scores (Randolph, 1998). 
Procedure 
Data were extracted archivally from a private neuropsychology practice on the 
East Coast of the United States. Patients were administered the MMPI-2, symptom 
validity tests (MCI/MSVT), and the RBANS as part of their clinical evaluations. 
Demographic information gleaned from a record review included sex, age, ethnicity, and 
highest education level attained. 
Participants were coded on categorical variables. The first variable was the reason 
for referral or the type of evaluation that was conducted (e.g., personal injury, medical 
disability, or general cognitive complaints). Participants were also coded regarding the 
potential for secondary gain at the time of the evaluation (e.g., personal injury lawsuit, 
workers' compensation claims, and private insurance disability claims) and were 
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compared with patients with general neuropsychological complaints who have no 
apparent secondary gain from the results of the evaluation. In addition, participants were 
grouped according to pass/fail performance on the MSVT and MMPI-2-RF over-
reporting scales, as determined by cutoff scores on the respective test manuals. 
Specifically, the recommended cutoff percentages for the MSVT that were utilized in this 
study was 85% or less for the immediate, delayed, and consistency indices, a cutoff of 
70% or less on the paired associates trial, and 55% for the free recall trial (Green, 2004). 
Individuals who failed the MSVT were assigned to the "fail SVT" group while those who 
passed were assigned to the "pass SVT" group where binary classification was required. 
Analyses that grouped participants based on pass/fail performance on the MMPI-2-RF 
implemented recommended cutoff scores found in the manual, including a T score of 99 
for FBS-r and Fs and a T score of 100 for RBS. Continuous variables included raw and T 
score results from the MMPI-2-RF over-reporting scales, including the FBS-r and Fs, and 
the RBS, as well as percentage scores collected from the MCI and the MSVT, and 
standard scores from the RBANS index scores. 
Questions to be answered by the Current Study 
1. Do scores on the MMPI-2-RF over-reporting scales predict symptom validity test 
performance? 
2. Do scores on the MMPI-2-RF over-reporting scales predict subjective memory 
complaints? 
3. Does this performance translate to ability test performance, in this case, the 
RBANS? 
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4. What are the best cutoff scores on the MMPI-2-RF over-reporting scales to 
optimize sensitivity, specificity, positive predictive power, and negative 
predictive power? 
Data Analyses 
Statistical analyses were calculated using SPSS, Version 18.0 (SPSS, Chicago, 
IL). Alpha was set at .05 for all analyses. Two-tailed Pearson correlations were 
conducted with the MMPI-2-RF validity scales and continuous data obtained from each 
measure utilized in the study. 
Hierarchical regression analyses were also utilized to assess the ability of the 
MMPI-2-RF over-reporting scales to predict performance on a symptom validity test 
(Green's MSVT), after accounting for age, sex, ethnicity, highest education level 
attained. To examine the unique contributions of the over-reporting scales and 
demographic variables with respect to both continuous scores on the MSVT and pass/fail 
group categorization, hierarchical multiple regression analyses and hierarchical binary 
logistic regression analyses were performed, respectively. Performance on each MSVT 
subscale was used as dependent variables (Immediate Recall, Delayed Recall, Paired 
Associates, Free Recall, and the Consistency index) and the order of independent 
variables were entered in four steps. The independent variables in each analysis were (1) 
demographic variables, (2) Fs, (3) FBS-r, (4), RBS. The order of entry was varied until 
each option was exhausted. 
Hierarchical regression analyses were also employed to examine the ability of the 
MMPI-2-RF over-reporting scales to predict performance on a measure of subjective 
memory complaints (Green's MCI). Since an MCI manual supplying relative cut-off 
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scores has not been published on this measure to date, hierarchical linear regression 
analyses were utilized on continuous data only. Analyses examined relative performance 
on first six scales of the MCI (plausible memory complaints) and on the final three scales 
(implausible memory complaints) to determine the relationship with the MMPI-2-RF 
over-reporting scales. Performance on each MCI scale was explored by entering the 
following independent variables: (1) demographic variables, (2) Fs, (3) FBS-r, (4), RBS. 
The order of entry was varied until each option was exhausted. 
To determine the relationship among MMPI-2-RF scales and ability test 
performance, hierarchical regression analyses were conducted using the subtest scores of 
the RBANS as at outcome measure. In this study, RBANS performance was 
hypothesized to decline as scores on over-reporting scales increased. Scores on RBANS 
substantive scales were compared by dividing the sample into participants identified as 
over-reporting on at least one MMPI-2-RF validity scale versus valid respondents using 
independent t-tests. 
Finally, Hit Rate, Sensitivity, Positive Predictive Power, and Negative Predictive 
Power were calculated at cutting scores of T> 80, 90,99,105, and 110 for Fs and FBS 
while cut scores of T > 80,90,100, 105, and 110 for RBS were utilized to predict 
classification status based on the MSVT. However, these analyses were limited in 
practical utility due to the small sample size. 
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RESULTS 
Prediction of symptom validity test performance by MMPI-2-RF Fs, FBS-r, and RBS, 
controlling for demographic characteristics 
The RBS had the largest effect size difference between those who passed Green's 
MSVT (n = 55) and those who failed (n = 15) (Table 1). However, this analysis was 
limited by the small number of participants in the MSVT fail group (21%). As expected, 
those who failed Green's MSVT scored higher and subsequently demonstrated more 
negative response bias than those who passed the MSVT. Results of Pearson correlations 
showed that RBS was most strongly related to the trials of Green's MSVT while FBS-r 
showed some mild association (Table 2). Means and standard deviations of MSVT scale 
performance based on MMPI-2-RF valid/invalid classification status are presented in 
Table 3. 
Means and standard deviations of the MMPI-2-RF over-reporting scales based on 
Green's Medical Symptom Validity Test pass/fail classification status 
Table 1 
MMPI-2-RF scales MSVT pass 
M ( S D )  
MSVT fail 
M ( S D )  
Cohen's d  
RBS 75.34 (15.72) 87.87 (12.53) 0.88 
FBS-r 71.22(13.99) 78.53 (9.14) 0.62 
Fs 73.00(19.67) 74.87(15.98) 0.10 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
•Significant at the .01 level 
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Table 2 
Linear correlations between Green's MSVT scales and the MMPI-2-RF over-reporting 
scales 
Green's MSVT Scales RBS FBS-r Fs 
Immediate Recall -.26* -.15 -.11 
Delayed Recall -.35** -21* -.15 
Paired Associates -.41** -21* -.15 
Free Recall -.37** -.09 -.09 
Consistency Index -.31** -.30 -.12 
Note. Green's MSVT: Green's Medical Symptom Validity Test; RBS: Response Bias Scale; FBS-r: Fake 
Bad Scale—Revised; Fs: Infrequent Somatic Symptoms Scale. 
* Significant at the .05 level 
••Significant at the .01 level 
Table 3 
Means and standard deviations of performance on Green's MSVT scores based on 
MMPI-2-RF over-reporting scales pass/fail classification status 
Green's MSVT MMPI-2-RF valid 
M ( S D )  
MMPI-2-RF invalid 
M ( S D )  
Cohen's d  
Immediate Recall 95.73 (10.99) 96.66 (5.56) 0.11 
Delayed Recall 91.25(18.14) 93.00(10.65) 0.12 
Paired Associates 88.36 (17.40) 87.00 (20.33) 0.07 
Free Recall 59.16(21.55) 56.66 (23.41) 0.11 
Consistency Index 91.62(17.36) 93.00 (9.78) 0.10 
Note. Green's MSVT: Green's Medical Symptom Validity Test. 
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Hierarchical regression analyses were performed to examine the ability of the 
MMPI-2-RF over-reporting scales to predict performance on the MSVT Immediate 
Recall (IR), Delayed Recall (DR), Paired Associates (PA), Free Recall (FR), and 
Consistency Index (CNS), after accounting for age, gender, ethnicity, and highest level of 
education obtained. Specifically, MSVT IR, DR, PA, FR and CNS were used as the 
dependent variables, each in separate analyses, while Fs, FBS-r, and RBS were entered 
into sequential blocks of the regression. To determine the incremental validity of each 
respective scale after accounting for demographic variables, hierarchical multiple 
regression analyses were performed that varied the order of each independent variable 
until each potential option was exhausted. 
RBS added incremental variance when entered in the second step, 
R change = . 124 (Table 4). The addition of FBS-r and Fs did not significantly improve 
prediction above and beyond the RBS in this sample, R2 change = .017, F = 2.54, ns and 
R2 change = .030. F = 2.58, ns, respectively. When FBS-r was entered before RBS, it 
also produced a significant /?2 change, although this value was lower than the value for 
RBS (Tables 5,6, and 7). Variance inflation factors raised no significant concerns about 
multicollinearity. Independence of errors was also found, Durbin Watson Test = 2.08. 
The assumption of homoscedasticity was met through inspection of a scatterplot while 
normality of residuals was demonstrated through a histogram and p-p plot. 
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Table 4 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MSVT 
Delayed Recall trial performance when RBS was entered in step two, FBS-r in step three, 
and Fs in step four 
Variable R  R 2 AdjR2 R2change F(change) df change sig 
Step 1 
Demographics .232 .054 -.004 .054 .925 (4, 65) .455 
Step 2 
RBS .422 .178 .114 .124 9.65 (5,64) .003 
Step 3 
FBS-r .442 .195 .118 .017 1.35 (6, 63) .249 
Step 4 
Fs .475 .225 .138 .030 2.43 (7, 62) .124 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
Table 5 
Hierarchical regression analysis of the MMP1-2-RF over-reporting scales and MSVT 
Delayed Recall trial performance with FBS-r in step two, RBS in step three, and Fs in 
step four 









.054 -.004 .054 
.149 .083 .095 
.195 .118 .046 
.225 .138 .030 
.925 (4,65) .455 
7.17 (5,64) .009 
3.60 (6,63) .062 
2.43 (7,62) .124 




Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MSVT 
Delayed Recall trial performance with Fs in step two, RBS in step three and FBS-r in 
step four 
Variable R R2 AdjR2 R2change /•"(change) df change sig 
Step 1 
Demographics .232 .054 -.004 .054 .925 (4,65) .455 
Step 2 
Fs .248 .062 -.012 .008 .526 (5,64) .471 
Step 3 
RBS .443 .196 .120 .135 10.57 (6,63) .002 
Step 4 
FBS-r .475 .225 .138 .029 2.33 (7,62) .132 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
Table 7 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MSVT 
Delayed Recall trial performance with Fs in step two, FBS-r in step three, and RBS in 
step four 
Variable R R2 AdjR2 R2change F(change) df change sig 
Step 1 
Demographics .232 .054 -.004 .054 .925 (4,65) .455 
Step 2 
Fs .248 .062 -.012 .008 .526 (5,64) .471 
Step 3 
FBS-r .393 .154 .074 .093 6.92 (6,63) .011 
Step 4 
RBS .475 .225 .138 .030 5.68 (7,62) .020 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
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With respect to performance on the MSVT Paired Associates trial, the final model 
had an R2 value of .225. When RBS was entered in the final step, 3% additional variance 
was accounted for (Table 8). As in the DR trial, addition of FBS-r and Fs did not account 
for significantly more variance after RBS was entered first, R2 change = .012, F = 3.41, 
ns and /?2 change = .023, F = 3.25, ns, respectively (Table 8). However, FBS-r 
significantly predicted performance on this trial when entered prior to RBS, thus 
demonstrating utility in predicting performance on the MSVT (Tables 9, 10, and 11). 
Variance inflation factors raised no significant concerns about multicollinearity. 
Independence of errors was also found, Durbin Watson Test = 2.16. Review of a 
scatterplot demonstrated homogeneity of variance while normality of residuals was 
indicated through a histogram and p-p plot. 
Table 8 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MSVT 
Paired Associates trial performance with RBS entered in step two, FBS-r in step three, 
and Fs in step four 
Variable R R2 AdjR2 R2change F(change) df change sig 
Step 1 
Demographics .286 .082 .025 .082 1.45 (4, 65) .228 
Step 2 
RBS .483 .234 .174 .152 12.67 (5,64) .001 
Step 3 
FBS-r .495 .245 .173 .012 .98 (6, 63) .326 
Step 4 
Fs .518 .269 .186 .023 1.98 (7, 62) .165 




Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MSVT 
Paired Associates trial performance with FBS-r entered in step two, RBS in step three, 
and Fs in step four 
Variable R R? AdjR2 R2 change /-"(change) df change sig 
Step 1 
Demographics .286 .082 .025 .082 1.45 (4,65) .228 
Step 2 
FBS-r .423 .179 .114 .097 7.53 (5,64) .008 
Step 3 
RBS .495 .245 .173 .067 5.57 (6,63) .021 
Step 4 
Fs .518 .269 .186 .023 1.98 (7,62) .165 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
Table 10 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MSVT 
Paired Associates trial performance with Fs entered in step two, RBS in step three, and 
FBS-r in step four 
Variable R R? AdjR2 R2 change F(change) df change sig 
Step 1 
Demographics .286 .082 .025 .082 1.45 (4,65) .228 
Step 2 
Fs .311 .097 .026 .015 1.04 (5,64) .311 
Step 3 
RBS .498 .248 .177 .152 12.71 (6,63) .001 
Step 4 
FBS-r .518 .269 .186 .020 1.73 (7,62) .193 




Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MSVT 
Paired Associates trial performance with Fs entered in step two, FBS-r in step three, and 
RBS in step four 
Variable R R2 AdjR2 /f2 change F(change) df change sig 
Step 1 
Demographics .286 .082 .025 .082 1.45 (4, 65) .228 
Step 2 
Fs .311 .097 .026 .015 1.04 (5,64) .311 
Step 3 
FBS-r .424 .180 .102 .083 6.39 (6,63) .014 
Step 4 
RBS .518 .269 .186 .089 7.53 (7,62) .008 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
RBS also accounted for a significant portion of the variance on the MSVT's Free 
Recall Trial, as it explained 12% of the variance, /?2 change = .119, F change (5, 64) = 
9.55, p < .01 (Table 12). The FBS-r and Fs did not provide significant incremental 
validity to the model, R2 change = .008, F = 2.84, ns and R2 change = .65, F = 1.22, ns, 
respectively. Unlike other MSVT scales, FBS-r did not significantly predict 
performance, even when entered before RBS (Tables 13, 14, and 15). Variance inflation 
factors raised no significant concerns about multicollinearity. Independence of errors was 
also found, Durbin Watson Test = 2.03. The assumptions of homoscedasticity and 




Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MSVT 
Free Recall trial performance 
Variable R R2 AdjR2 R2 change F(change) df change sig 
Step 1 
Demographics .294 .086 .030 .086 1.53 (4,65) .203 
Step 2 
RBS .453 .205 .174 .119 9.55 (5,64) .003 
Step 3 
FBS-r .461 .213 .138 .008 .65 (6,63) .423 
Step 4 
Fs .478 .228 .141 .015 1.22 (7,62) .274 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
Table 13 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MSVT 
Free Recall trial performance with FBS-r in step two, RBS in step three, and Fs in step 
four 
Variable R AdjR2 R2 change F(change) df change sig 
Step 1 
Demographics .294 .086 .030 .086 1.53 (4,65) .203 
Step 2 
FBS-r .318 .101 .031 .015 1.06 (5,64) .306 
Step 3 
RBS .461 .213 .138 .112 8.95 (6,63) .004 
Step 4 
Fs .478 .228 .141 .015 1.22 (7,62) .274 




Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MSVT 
Free Recall trial performance with Fs in step two, RBS in step three, and FBS-r in step 
four 
Variable R AdjR2 R2 change F(change) df change sig 
Step 1 
Demographics .294 .086 .030 .086 1.53 (4,65) .203 
Step 2 
Fs .304 .092 .151 .006 .44 (5,64) .510 
Step 3 
RBS .474 .225 .151 .132 10.77 (6,63) .002 
Step 4 
FBS-r .478 .228 .141 .003 .26 (7,62) .612 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
Table 15 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MSVT 
Free Recall trial performance with Fs in step two, FBS-r in step three, and RBS in step 
four 
Variable R AdjR2 R2 change F(change) df change sig 
Step 1 
Demographics .294 .086 .030 .086 1.53 (4,65) .203 
Step 2 
Fs .304 .092 .022 .006 .44 (5,64) .510 
Step 3 
FBS-r .319 .102 .016 .009 .64 (6,63) .426 
Step 4 
RBS .478 .228 .141 .127 10.16 (7,62) .002 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
RBS accounted for significantly more variance than demographic variables on the 
MSVT's Immediate Recall trial, R2 change = .081, p < .05 (Table 16). FBS-r and Fs did 
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not provide significant contributions to the incremental validity of this trial when entered 
both before and after RBS (Tables 17, 18, and 19). Variance inflation factors raised no 
significant concerns about multicollinearity. Independence of errors was also found, 
Durbin Watson Test = 1.96. Homogeneity of variance was observed on a scatterplot 
while residuals appeared normally distributed on a histogram and p-p plot. 
Table 16 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MSVT 
Immediate Recall trial performance 
Variable R R2 AdjR2 R2change F(change) df change sig 
Step 1 
Demographics .094 .009 -.052 .009 .146 (4, 65) .964 
Step 2 
RBS .300 .090 .019 .081 5.73 (5,64) .020 
Step 3 
FBS-r .302 .091 .005 .001 .077 (6, 63) .783 
Step 4 
Fs .324 .105 .004 .014 .94 (7, 62) .335 




Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MSVT 
Immediate Recall trial performance with FBS-r in step two, RBS in step three, and Fs in 
step four 
Variable R R2 AdjR? R2 change F(change) df change sig 
Step 1 
Demographics .094 .009 -.052 .009 .146 (4,65) .964 
Step 2 
FBS-r .212 .045 -.030 .036 2.42 (5,64) .125 
Step 3 
RBS .302 .091 .005 .046 3.22 (6,63) .078 
Step 4 
Fs .324 .105 .004 .014 .94 (7,62) .335 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
Table 18 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MSVT 
Immediate Recall trial performance with Fs in step two, RBS in step three, and FBS-r in 
step four 
Variable R R2 AdjR2 R2 change F(change) df change sig 
Step 1 
Demographics .094 .009 -.052 .009 .146 (4,65) .964 
Step 2 
Fs .121 .015 -.062 .006 .372 (5,64) .544 
Step 3 
RBS .318 .101 .016 .087 6.07 (6,63) .016 
Step 4 
FBS-r .324 .105 .004 .004 .259 (7,62) .613 




Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MSVT 
Immediate Recall trial performance with Fs in step two, FBS-r in step three, and RBS in 
step four 
Variable R R2 AdjR2 R2change F(change) df change sig 
Step 1 
Demographics .094 .009 -.052 .009 .146 (4, 65) .964 
Step 2 
Fs .121 .015 -.062 .006 .372 (5,64) .544 
Step 3 
FBS-r .213 .045 -.046 .031 2.03 (6, 63) .159 
Step 4 
RBS .324 .105 .004 .060 4.13 (7,62) .046 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
Both RBS and FBS-r significantly predicted performance on the MSVT 
Consistency index, though neither provided incremental validity when added after one 
another (Tables 21, 22, 23, and 24). Variance inflation factors raised no significant 
concerns about multicollinearity. Independence of errors was also found, Durbin 
Watson Test = 2.07. The assumptions of homoscedasticity and normality of residuals 
were also met through inspection of a scatterplot, histogram, and p-p plot. 
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Table 20 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MSVT 
Consistency Index 
Variable R R* AdjR2 R2 change F(change) df change sig 
Step 1 
Demographics .204 .042 -.017 .042 .708 (4,65) .589 
Step 2 
RBS .368 .135 .068 .094 6.92 (5,64) .011 
Step 3 
FBS-r .414 .172 .093 .036 2.76 (6,63) .101 
Step 4 
Fs .441 .194 .104 .023 1.76 (7,62) .189 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
Table 21 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MSVT 
Consistency Index with FBS-r in step two, RBS in step three, and Fs in step four 
Variable R R? AdjR2 R2 change F(change) df change sig 
Step 1 
Demographics .204 .042 -.017 .042 .708 (4,65) .589 
Step 2 
FBS-r .389 .151 .085 .109 8.25 (5,64) .006 
Step 3 
RBS .414 .172 .093 .020 1.55 (6,63) .218 
Step 4 
Fs .441 .194 .104 .023 1.76 (7,62) .189 




Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MSVT 
Consistency Index with Fs in step two, RBS in step three, and FBS-r in step four 
Variable R Z?2 AdjR2 R2change /•"(change) df change sig 
Step 1 
Demographics .204 .042 -.017 .042 .708 (4, 65) .589 
Step 2 
Fs .224 .050 -.024 .008 .569 (5, 64) .453 
Step 3 
RBS .381 .145 .064 .095 7.00 (6,63) .010 
Step 4 
FBS-r .441 .194 .104 .049 3.80 (7, 62) .056 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
Table 23 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MSVT 
Consistency Index with Fs in step two, FBS-r in step three, and RBS in step four 
Variable R Z?2 AdjR2 R2change /"(change) df change sig 
Step 1 
Demographics .204 .042 -.017 .042 .708 (4, 65) .589 
Step 2 
Fs .224 .050 -.024 .008 .569 (5,64) .453 
Step 3 
FBS-r .397 .158 .078 .108 8.05 (6,63) .006 
Step 4 
RBS .441 .194 .104 .037 .037 (7, 62) .098 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
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After conducting multiple analyses, RBS appeared to be the best predictor of 
performance on the MSVT when added in the second step, as neither FBS-r nor Fs 
provided incremental validity above and beyond what was explained by RBS. When 
FBS-r was entered before RBS, it significantly predicted performance as well. The RBS 
added incremental validity to FBS-r on the paired associates and free recall trials, though 
not on the immediate and delayed recall trials and consistency index. Multiple analyses 
were conducted and RBS was found to account for a significant amount of the variance 
on the MSVT DR, PA, and FR scales. Demographic variables did not significant account 
for performance on any MSVT measures. 
To investigate the utility of the MMPI-2-RF over-reporting scales in predicting 
overall MSVT performance, binary logistic regressions were conducted utilizing MSVT 
Pass/Fail classification as a dependent variable. As in the previous analyses, 
demographic variables were entered in the first step of the model followed by MMPI-2-
RF over-reporting scales. The order of these scales was subsequently varied until all 
possible options were exhausted to determine the best predictive model. 
After controlling for age, gender, ethnicity, and highest education level attained, 
RBS predicted pass/fail classification status on the MSVT (Table 24). When only the 
constant was included, the model correctly classified 78.6% of patients. The addition of 
RBS as a predictor significantly increased the percentage of correctly classified patients 
to 81.4%. Results of this analyses indicated that Fs and FBS-r did not provide significant 
incremental validity above and beyond what was explained by RBS. Assumptions of the 
logistic regression were met, such that the linearity of the logit was proven through 
nonsignificant interaction terms based on the predictors and the natural log of itself. 
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However, the analyses were underpowered as a sample size of 77 is small for logistic 
regression. Furthermore, a linear regression analysis using the same outcome and 
predictors was run to determine the proportions and subsequent eigenvalues of the scaled, 
uncentered cross-products matrix. No multicollinearity was found as a result of this 
model. 
Table 24 
Binary logistic regression analysis of the MMPI-2-RF over-reporting scales and MSVT 
pass/fail classification 
Variable B ( S E )  Cox and Snell R2 -2 Log Likelihood Wald £ change p-value 

























RBS .27 (0.10) .16 60.71 6.79 8.36 .004 
Block 3 
Fs -.37 (0.20) .21 53.56 3.51 5.15 .061 
Block 4 
FBS-r .21 (0.13) .24 53.76 2.77 3.06 .240 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
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Predicting subjective memory complaints on Green's Memory Complaints Inventory 
(MCI) by MMPI-2-RF Fs, FBS-r, and RBS, controlling for demographic characteristics 
Means and standard deviations for MCI scores based on failure of one or more 
MMPI-2-RF over-reporting scale are presented in Table 25. Results of Pearson 
correlations showed significant, positive correlations among the MMPI-2-RF over-
reporting scales and subjective memory complaints (Table 26). In general, these data 
suggest that as patients endorsed more subjective memory complaints on the MCI, they 
tended to endorse items from RBS, FBS-r, and Fs at a higher rate. With respect to 
probable memory complaints, RBS demonstrated moderate, positive associations with 
general memory problems, numeric information problems, visuospatial memory 
problems, verbal memory problems, and memory interferes with work. Small, positive 
correlations were observed between FBS-r and scales measuring probable memory 
complaints, as well. A small, positive correlation was demonstrated between Fs and 
memory interferes with work. On measures of improbable memory complaints, RBS was 
moderately associated with impairment of remote memory and amnesia for complex 
behavior while FBS-r was mildly associated with these same scales. A mild association 
was demonstrated between Fs and amnesia for complex behavior. 
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Table 25 
Means and standard deviations of performance on Green's MSVT scores based on 
MMPI-2-RF over-reporting scales pass/fail classification status 
Green's MCI MMPI-2-RF valid 
M ( S D )  
MMPI-2-RF invalid 
M ( S D )  
Cohen's d 
General Memory Problems 38.69 (22.63) 44.68 (25.95) 0.11 
Numerical Information Problems 43308 (24.89) 47.31 (26.34) 0.12 
Visuospatial Memory Problems 32.88 (24.62) 47.31 (26.34) 0.07 
Verbal Memory Problems 53.85 (27.77) 60.63 (25.88) 0.11 
Memory Interferes with Work 45.31 (28.35) 54.69 (29.91) 0.10 
Impairment of Remote Memory 23.52 (18.79) 25.63 (18.41) 0.10 
Amnesia for Complex Behavior 29.60 (21.64) 37.36 (24.06) 0.10 
Amnesia for Antisocial Behavior 11.60(14.21) 7.75 (6.44) 0.10 
Note. Green's MSVT: Green's Medical Symptom Validity Test. 
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Table 26 
Linear correlations between Green's MSVT scales and the MMP1-2-RF over-reporting 
scales 
Green's MSVT Scales RBS FBS-r Fs 
Probable Memory Complaints 
General Memory Problems .54** .31* .22 
Numeric Information Problems .49** .26* .12 
Visuospatial Memory Problems .42** .26* .16 
Verbal Memory Problems .55** .32* .23 
Pain Interferes with Memory .17 .32* .18 
Memory Interferes with Work .53** .38** .27* 
Improbable Memory Complaints 
Impairment of Remote Memory .46** .26* .20 
Amnesia for Complex Behavior .50** .29* .36* 
Amnesia for Antisocial Behavior .24 .22 .20 
Note. Green's MSVT: Green's Medical Symptom Validity Test; RBS: Response Bias Scale; FBS-r: Fake 
Bad Scale—Revised; Fs: Infrequent Somatic Symptoms Scale. 
* Significant at the .05 level 
••Significant at the .01 level 
Hierarchical linear regression analyses were also used to predict the variability 
among probable and improbable subjective memory complaints reported on Green's 
MCI. As in the MSVT analyses, the independent variables were entered in four blocks. 
Demographic variables were entered in the model in the first block, followed by FBS-r, 
Fs, and RBS in the subsequent three blocks for each of the nine MCI scales. In this way, 
it was possible to examine the predictive utility of the MMPI-2-RF over-reporting 
variables, controlling for the potential effects of demographic variables. 
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Overall, RBS explained a significant amount of the variance in subjective 
memory complaints, based on performance on the MCI scales that assessed general 
memory problems, numeric information problems, visuospatial memory problems, verbal 
memory problems, memory interferes with work, impairment of remote memory, and 
amnesia for complex behavior. FBS-r also provided significant predictive validity on 
scales measuring pain interfering with memory and amnesia for antisocial behavior. 
Specifically, RBS explained 28% of the variance on the General Memory 
Problems scale (Table 27). The addition of Fs and FBS-r did not add significant 
incremental validity to the model when added after RBS. When entered before RBS, 
FBS-r also predicted a significant amount of variance (Tables 28,29, and 30). Variance 
inflation factors raised no significant concerns about multicollinearity. Independence of 
errors was also found, Durbin Watson Test = 2.53. The assumptions of homoscedasticity 
and normality of residuals were also met through inspection of a scatterplot, histogram, 
and p-p plot, respectively. 
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Table 27 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI 
General Memory Complaints scale 
Variable R /f2 AdjR2 R2change F(change) df change sig 
Step 1 
Demographics .154 .024 -.038 .024 .384 (4, 63) .819 
Step 2 
RBS .548 .301 .244 .277 24.54 (5,62) .000 
Step 3 
FBS-r .556 .309 .241 .008 .73 (6, 61) .395 
Step 4 
Fs .556 .309 .229 .000 .018 (7,60) .895 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
Table 28 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI 
General Memory Complaints scale with FBS-r in step two, RBS in step three, and Fs in 
step four 









.024 -.038 .024 
.107 .035 .083 
.301 .232 .194 
.309 .229 .008 
.384 (4,63) .819 
5.78 (5,62) .019 
16.89 (6,61) .000 
.732 (7,60) .396 




Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI 
General Memory Complaints scale with Fs in step two, RBS in step three, and FBS-r in 
step four 
Variable R Z?2 AdjR2 R2change F(change) df change sig 
Step 1 
Demographics .154 .024 -.038 .024 .384 (4,63) .819 
Step 2 
Fs .269 .072 -.003 .048 3.24 (5,62) .077 
Step 3 
RBS .556 .309 .241 .237 20.89 (6,61) .000 
Step 4 
FBS-r .556 .309 .229 .000 .018 (7,60) .895 




Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI 
General Memory Complaints scale with Fs in step two, FBS-r in step three, and RBS in 
step four 
Variable R R2 AdjR2 R2change F(change) df change sig 
Step 1 
Demographics .154 .024 -.038 .024 .384 (4, 63) .819 
Step 2 
Fs .269 .072 -.003 .048 3.24 (5, 62) .077 
Step 3 
FBS-r .340 .116 .029 .043 2.99 (6,61) .089 
Step 4 
RBS .556 .309 .229 .194 16.81 (7,60) .000 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
RBS scores and demographic variables also explained 23% of the variance on the 
Numeric Information Problems of the MCI, R2 change = .225, F (5, 62) = 18.69, p < .001 
(Table 31). The addition of Fs and FBS-r did not lead to a substantial increase in the 
amount of variance explained in this scale above and beyond RBS, although FBS-r 
predicted a significant amount of variance when entered before RBS (Tables 32, 33, and 
34). Variance inflation factors raised no significant concerns about multicollinearity. 
Independence of errors was also found, Durbin Watson Test = 2.50. Homogeneity of 
variance was observed on a scatterplot while residuals appeared normally distributed on a 
histogram and p-p plot. 
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Table 31 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI 
Numeric Information Problems scale 
Variable R R? AdjR2 R2 change /-"(change) df change sig 
Step 1 
Demographics .166 .028 -.034 .028 .448 (4,63) .773 
Step 2 
RBS .503 .253 .215 .225 18.69 (5,62) .000 
Step 3 
FBS-r .535 .286 .215 .033 2.81 (6,61) .099 
Step 4 
Fs .535 .286 .203 .000 .021 (7,60) .884 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
Table 32 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI 
Numeric Information Problems scale with FBS-r in step two, RBS in step three and Fs in 
step four 
Variable R R2 AdjR2 R2 change F(change) df change sig 
Step 1 
Demographics .166 .028 -.034 .028 .448 (4,63) .773 
Step 2 
FBS-r .294 .087 .013 .059 4.00 (5,62) .050 
Step 3 
RBS .509 .254 .180 .167 13.66 (6,61) .000 
Step 4 
Fs .535 .286 .203 .032 2.71 (7,60) .105 




Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI 
Numeric Information Problems scale with Fs in step two, RBS in step three, and FBS-r in 
step four 
Variable R AdjR2 R2 change F(change) df change sig 
Step 1 
Demographics .166 .028 -.034 .028 .448 (4,63) .773 
Step 2 
Fs .203 .041 -.036 .014 .877 (5,62) .353 
Step 3 
RBS .535 .286 .215 .245 20.88 (6,61) .000 
Step 4 
FBS-r .535 .286 .203 .000 .021 (7,60) .884 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
Table 34 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI 
Numeric Information Problems scale with Fs in step two, FBS-r in step three, and RBS-r 
in step four 
Variable R R2 AdjR2 R2 change F(change) df change sig 
Step 1 
Demographics .166 .028 -.034 .028 .448 (4,63) .773 
Step 2 
Fs .203 .041 -.036 .014 .877 (5,62) .353 
Step 3 
FBS-r .294 .087 -.003 .045 3.03 (6,61) .087 
Step 4 
RBS .535 .286 .203 .199 16.76 (7,60) .000 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
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RBS added incremental variance above and beyond the demographic variables 
when predicted scores on the Visuospatial Memory Problems scale when entered in the 
second step, /f2 change = .139, F change (5,62) = 10.89, p < .01 (Table 35). Addition of 
FBS-r and Fs did not significantly improve prediction above and beyond the RBS in this 
sample, although FBS-r significantly predicted performance on the visuospatial memory 
problems scale when entered before RBS (Tables 36, 37, and 38). Variance inflation 
factors raised no significant concerns about multicollinearity. Independence of errors was 
also found, Durbin Watson Test = 2.43. The assumptions of homoscedasticity and 
normality of residuals were also met through inspection of a scatterplot, histogram, and 
p-p plot. 
Table 35 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI 
Visuospatial Memory Problems scale 
Variable R R2 AdjR2 R2 change F(change) df change sig 
Step 1 
Demographics .258 .066 .007 .066 1.12 (4,63) .354 
Step 2 
RBS .454 .206 .142 .139 10.89 (5,62) .002 
Step 3 
FBS-r .461 .212 .135 .006 .48 (6,61) .490 
Step 4 
Fs .468 .219 .128 .000 .51 (7,60) .477 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
Table 36 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI 
Visuospatial Memory Problems scale with FBS-r in step two, RBS in step three, and Fs in 
step four 
Variable R Z?2 AdjR1 R2 change /•"(change) df change sig 
Step 1 
Demographics .258 .066 .007 .066 1.12 (4, 63) .354 
Step 2 
FBS-r .366 .134 .064 .067 4.81 (5,62) .032 
Step 3 
RBS .458 .210 .132 .076 5.85 (6,61) .019 
Step 4 
Fs .468 .219 .128 .009 .51 (7, 60) .401 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
Table 37 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI 
Visuospatial Memory Problems scale with Fs in step two, RBS in step three, and FBS-r in 
step four 
Variable R R2 AdjR2 R2 change F(change) df change sig 
Step 1 
Demographics .258 .066 .007 .066 1.12 (4,63) .354 
Step 2 
Fs .296 .087 .014 .021 1.42 (5,62) .238 
Step 3 
RBS .461 .212 .135 .125 9.67 (6,61) .003 
Step 4 
FBS-r .468 .219 .128 .000 .51 (7,60) .477 




Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI 
Visuospatial Memory Problems scale with Fs in step two, FBS-r in step three, and RBS in 
step four 
Variable R /f2 AdjR2 R2change F(change) df change sig 
Step 1 
Demographics .258 .066 .007 .066 1.12 (4, 63) .354 
Step 2 
Fs .296 .087 .014 .021 1.42 (5, 62) .238 
Step 3 
FBS-r .366 .134 .049 .047 3.30 (6, 61) .074 
Step 4 
RBS .468 .219 .128 .085 6.50 (7,60) .013 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
With respect to performance on the Verbal Memory Problems scale, RBS also 
accounted for a significant portion of the variance, R2 change = .283, F change (5, 62) = 
25.60, p < .001 (Table 39). As with the other scales, the addition of FBS-r and Fs did not 
account for significantly more variance. However, FBS-r predicted a significant amount 
of variance when entered before RBS (Tables 40,41, and 42). Variance inflation factors 
raised no significant concerns about multicollinearity. Independence of errors was also 
found, Durbin Watson Test = 2.78. Homogeneity of variance was observed on a 
scatterplot while residuals appeared normally distributed on a histogram and p-p plot. 
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Table 39 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI 
Verbal Memory Problems scale 
Variable R R2 AdjR2 R2 change F(change) df change sig 
Step 1 
Demographics .180 .032 -.029 .032 .526 (4,63) .717 
Step 2 
RBS .561 .315 .260 .283 25.60 (5,62) .000 
Step 3 
FBS-r .570 .325 .259 .010 .92 (6,61) .341 
Step 4 
Fs .572 .327 .249 .002 .16 (7,60) .691 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
Table 40 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI 
Verbal Memory Problems scale with FBS-r in step two, RBS in step three, and Fs in step 
four 
Variable R /P AdjR2 R2 change F(change) df change sig 
Step 1 
Demographics .180 .032 -.029 .032 .526 (4,63) .717 
Step 2 
FBS-r .360 .130 .060 .098 6.95 (5,62) .011 
Step 3 
RBS .562 .315 .248 .186 16.53 (6,61) .000 
Step 4 
Fs .572 .327 .249 .012 1.04 (7,60) .691 




Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI 
Verbal Memory Problems scale with Fs in step two, RBS in step three, and FBS-r in step 
four 
Variable R  R 2 A d j R 2  R 2  c h a n g e  F(change) df change sig 
Step 1 
Demographics .180 .032 -.029 .032 .526 (4,63) .717 
Step 2 
Fs .280 .079 .004 .046 3.11 (5,62) .083 
Step 3 
RBS .570 .325 .259 .247 22.30 (6,61) .000 
Step 4 
FBS-r .572 .237 .249 .002 .16 (7,60) .691 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
Table 42 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI 
Verbal Memory Problems scale with Fs in step two, FBS-r in step three, and RBS in step 
four 
Variable R R? AdjR2 R2change F(change) df change sig 
Step 1 
Demographics .180 .032 -.029 .032 .526 (4,63) .717 
Step 2 
Fs .280 .079 .004 .046 3.11 (5,62) .083 
Step 3 
FBS-r .368 .135 .050 .057 3.99 (6,61) .050 
Step 4 
RBS .572 .327 .249 .192 17.12 (7,60) .000 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
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RBS explained 25.7% of the variance in the Memory Interferes with Work scale, 
(Table 43). The addition of Fs and FBS-r did not add significant incremental validity to 
the model above and beyond what was explained by RBS. However, Fs predicted a 
significant amount of variance when entered prior to FBS-r and RBS while FBS-r 
significantly predicted performance when entered before RBS (Tables 44,45, and 46). 
Variance inflation factors raised no significant concerns about multicollinearity. 
Independence of errors was also found, Durbin Watson Test = 2.58. The assumptions of 
homoscedasticity and normality of residuals were also met through inspection of a 
scatterplot, histogram, and p-p plot, respectively. 
Table 43 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI 
Memory Interferes with Work scale 
Variable R Z?2 AdjR2 R2change F(change) df change sig 
Step 1 
Demographics .234 .055 -.055 .055 .916 (4, 63) .460 
Step 2 
RBS .558 .311 .256 .257 23.09 (5,62) .000 
Step 3 
FBS-r .559 .313 .245 .002 .138 (6, 61) .712 
Step 4 
Fs .575 .330 .252 .017 1.54 (7, 60) .220 




Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI 
Memory Interferes with Work scale with FBS-r in step two, RBS in step three, and Fs in 
step four 
Variable R R^ AdjF? R2 change F(change) df change sig 
Step 1 
Demographics .234 .055 -.055 .055 .916 (4,63) .460 
Step 2 
FBS-r .448 .201 .136 .146 11.29 (5,62) .001 
Step 3 
RBS .570 .325 .259 .125 11.27 (6,61) .001 
Step 4 
Fs .575 .330 .252 .005 .44 (7,60) .509 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
Table 45 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI 
Memory Interferes with Work scale with Fs in step two, RBS in step three, and FBS-r in 
step four 
Variable R R2 AdjR2 R2change F(change) df change sig 
Step 1 
Demographics .234 .055 -.055 .055 .916 (4, 63) .460 
Step 2 
Fs .344 .118 .047 .063 4.46 (5,62) .039 
Step 3 
RBS .559 .313 .245 .195 17.28 (6,61) .000 
Step 4 
FBS-r .575 .330 .252 .017 1.54 (7,60) .220 




Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI 
Memory Interferes with Work scale with Fs in step two, FBS-r in step three, and RBS in 
step four 
Variable R R2 AdjR2 R2change F(change) df change sig 
Step 1 
Demographics .234 .055 -.055 .055 .916 (4,63) .460 
Step 2 
Fs .344 .118 .047 .063 4.46 (5,62) .039 
Step 3 
FBS-r .454 .207 .128 .088 6.78 (6,61) .012 
Step 4 
RBS .575 .330 .252 .124 11.07 (7,60) .001 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
With respect to performance on the improbable complaints scales, RBS accounted 
for 18% of the variance on the Impairment of Remote Memory scale (Table 47). Fs and 
FBS-r did not produce a significant increase in the amount of variance explained, though 
FBS-r predicted significant variance when entered in step two following demographics 
(Tables 48,49,50). Variance inflation factors raised no significant concerns about 
multicollinearity. Independence of residuals was also found, Durbin Watson Test = 2.12. 
Homogeneity of variance was observed on a scatterplot while residuals appeared 
normally distributed on a histogram and p-p plot. 
69 
Table 47 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI 
Impairment of Remote Memory scale 
Variable R /?* AdjR? R2 change F(change) df change sig 
Step 1 
Demographics .291 .085 .026 .085 1.45 (4,63) .227 
Step 2 
RBS .512 .262 .202 .177 14.90 (5,62) .000 
Step 3 
FBS-r .516 .266 .194 .004 .36 (6,61) .552 
Step 4 
Fs .517 .267 .181 .001 .05 (7,60) .824 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
Table 48 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI 
Impairment of Remote Memory scale with FBS-r in step two, RBS in step three, and Fs in 
step four 
Variable R ^ AdjR2 R2 change F(change) df change sig 
Step 1 
Demographics .291 .085 .026 .085 1.45 (4,63) .227 
Step 2 
FBS-r .379 .144 .075 .059 4.28 (5,62) .043 
Step 3 
RBS .512 .262 .189 .118 9.78 (6,61) .003 
Step 4 
Fs .517 .267 .181 .005 .40 (7,60) .531 




Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI 
Impairment of Remote Memory scale with Fs in step two, RBS in step three, and FBS-r in 
step four 
Variable R /?* AdjR2 R2 change F(change) df change sig 
Step 1 
Demographics .291 .085 .026 .085 1.45 (4,63) .227 
Step 2 
Fs .343 .118 .047 .033 2.33 (5,62) .132 
Step 3 
RBS .516 .266 .194 .149 12.35 (6,61) .001 
Step 4 
FBS-r .517 .267 .181 .001 .05 (7,60) .824 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
Table 50 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI 
Impairment of Remote Memory scale with Fs in step two, FBS-r in step three, and RBS in 
step four 
Variable R R2 AdjR2 R2 change F(change) df change 
sig 
Step 1 
Demographics .291 .085 .026 .085 1.45 (4,63) .227 
Step 2 
Fs .343 .118 .047 .033 2.33 (5,62) .132 
Step 3 
FBS-r .386 .149 .065 .031 2.25 (6,61) .139 
Step 4 
RBS .517 .267 .181 .118 9.63 (7,60) .003 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
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Finally, RBS and demographic variables accounted for a significant portion of 
variance on the Amnesia for Complex Behavior scale, R2 change = .22, F change (5, 62) 
= 19.02, p < .001 (Table 51). The addition of Fs and FBS-r did not add significant 
incremental validity to the model when entered after RBS. However, FBS-r and Fs 
significantly predicted performance when entered in step two following demographics, 
though RBS still explained further variance above and beyond these measures (Tables 52, 
53, and 54). Variance inflation factors raised no significant concerns about 
multicollinearity. Independence of errors was also found, Durbin Watson Test = 2.23. 
The assumptions of homoscedasticity and normality of residuals were also met through 
inspection of a scatterplot, histogram, and p-p plot. 
Table 51 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI 
Amnesia for Complex Behavior scale 
Variable R R* AdjR2 R2 change F(change) df change sig 
Step 1 
Demographics .253 .064 .005 .064 1.07 (4,63) .376 
Step 2 
RBS .533 .284 .228 .220 19.02 (5,62) .000 
Step 3 
FBS-r .545 .297 .228 .013 1.13 (6,61) .291 
Step 4 
Fs .545 .297 .215 .000 .012 (7,60) .914 




Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI 




R R2 AdjR2 R2change F(change) df change 
Step 1 
Demographics .253 .064 .005 .064 1.07 (4, 63) .376 
Step 2 
FBS-r .389 .151 .083 .088 6.40 (5,62) .014 
Step 3 
RBS .534 .285 .215 .134 11.41 (6,61) .001 
Step 4 
Fs .545 .297 .215 .012 .994 (7,60) .323 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
Table 53 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI 
Amnesia for Complex Behavior scale with Fs in step two, RBS in step three, and FBS-r in 
step four 
Variable R R* AdjR? R2 change F(change) df change sig 
Step 1 
Demographics .253 .064 .005 .064 1.07 (4,63) .376 
Step 2 
Fs .438 .192 .127 .128 9.82 (5,62) .003 
Step 3 
RBS .545 .297 .228 .105 9.09 (6,61) .004 
Step 4 
FBS-r .545 .297 .215 .000 .012 (7,60) .914 




Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI 
Amnesia for Complex Behavior scale with Fs in step two, FBS-r in step three, and RBS in 
step four 
Variable R R2 AdjR2 R2change F(change) df change sig 
Step 1 
Demographics .253 .064 .005 .064 1.07 (4, 63) .376 
Step 2 
Fs .438 .192 .127 .128 9.82 (5,62) .003 
Step 3 
FBS-r .460 .212 .134 .020 1.53 (6, 61) .221 
Step 4 
RBS .545 .297 .215 .085 7.27 (7,60) .009 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
FBS-r and demographic variables explained 12% of the variance on the Pain 
Interferes with Memory scale of the MCI (Table 55). RBS and Fs did not provide 
significant incremental validity to the model and FBS-r continued to explain significant 
variance above and beyond Fs and RBS when entered at various points in the model 
(Tables 56,57, and 58). Variance inflation factors raised no significant concerns about 
multicollinearity. Independence of errors was also found, Durbin Watson Test = 1.85. 
Homogeneity of variance was observed on a scatterplot while residuals appeared 
normally distributed on a histogram and p-p plot. 
74 
Table 55 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI Pain 
Interferes with Memory scale 
Variable R AdjR2 R2 change F(change) df change sig 
Step 1 
Demographics .317 .100 .043 .100 1.76 (4,63) .149 
Step 2 
FBS-r .468 .219 .143 .119 .063 (5,62) .003 
Step 3 
RBS .469 .220 .143 .001 .06 (6,61) .802 
Step 4 
Fs .469 .220 .129 .001 .050 (7,60) .824 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
Table 56 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI Pain 
Interferes with Memory scale with RBS in step two, FBS-r in step three, and Fs in step 
four 
Variable R R2 AdjR2 R2 change F(change) df change 
sig 
Step 1 
Demographics .317 .100 .043 .100 1.76 (4,63) .149 
Step 2 
RBS .359 .129 .059 .029 2.05 (5,62) .157 
Step 3 
FBS-r .469 .220 .143 .090 7.06 (6,61) .010 
Step 4 
Fs .469 .220 .129 .001 .050 (7,60) .824 




Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI Pain 
Interferes with Memory scale with Fs in step two, RBS in step three, and FBS-r in step 
four 
Variable R /?* AdjR2 R2 change F(change) df change sig 
Step 1 
Demographics .317 .100 .043 .100 1.76 (4,63) .149 
Step 2 
Fs .363 .132 .062 .031 2.23 (5,62) .141 
Step 3 
RBS .373 .139 .054 .007 .52 (6,61) .476 
Step 4 
FBS-r .469 .220 .129 .081 6.26 (7,60) .015 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
Table 58 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI Pain 
Interferes with Memory scale with Fs in step two, FBS-r in step three, and RBS in step 
four 
Variable R R2 AdjR2 R2 change F(change) df change sig 
Step 1 
Demographics .317 .100 .043 .100 1.76 (4,63) .149 
Step 2 
Fs .363 .132 .062 .031 2.23 (5,62) .141 
Step 3 
FBS-r .468 .219 .142 .087 6.82 (6,61) .011 
Step 4 
RBS .469 .220 .129 .001 .101 (7,60) .751 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
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The addition of FBS-r after demographic variables resulted in statistically 
significant prediction in the Amnesia for Antisocial Behavior scale when entered in step 
two (Table 59) but did not predict significant variance when entered after RBS and Fs 
(Tables 60, 61, and 62). Together, the variables explained 19% of the variance and Fs 
and RBS did not add significant predictive utility to the model. Variance inflation factors 
raised no significant concerns about multicollinearity. Independence of errors was also 
found, Durbin Watson Test = 2.12. The assumptions of homoscedasticity and normality 
of residuals were also met through inspection of a scatterplot, histogram, and p-p plot. 
Table 59 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI 
Amnesia for Antisocial Behavior scale 
Variable R Z?2 AdjR2 R2change F(change) df change sig 
Step 1 
Demographics .370 .137 .082 .137 2.49 (4, 63) .052 
Step 2 
FBS-r .439 .193 .128 .056 4.33 (5,62) .042 
Step 3 
RBS .445 .198 .119 .005 .38 (6, 61) .539 
Step 4 
Fs .451 .203 .110 .005 .39 (7, 60) .536 




Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI 
Amnesia for Antisocial Behavior scale with RBS in step two, FBS-r in step three, and Fs 
in step four 
Variable R R? AdjR? R2change F(change) df change sig 
Step 1 
Demographics .370 .137 .082 .137 2.49 (4, 63) .052 
Step 2 
RBS .417 .173 .107 .037 2.76 (5, 62) .101 
Step 3 
FBS-r .445 .198 .119 .025 1.86 (6, 61) .177 
Step 4 
Fs .451 .203 .110 .005 .39 (7, 60) .536 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
Table 61 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and MCI 
Amnesia for Antisocial Behavior scale with Fs in step two, FBS-r in step three, and RBS 
in step four 
Variable R R* AdjR2 R2 change F(change) df change sig 
Step 1 
Demographics .370 .137 .082 .137 2.49 (4,63) .052 
Step 2 
Fs .419 .175 .109 .039 2.92 (5,62) .093 
Step 3 
FBS-r .449 .202 .123 .026 2.02 (6,61) .161 
Step 4 
RBS .451 .203 .110 .001 .098 (7,60) .755 




Hierarchical regression analysis of the MMP1-2-RF over-reporting scales and MCI 
Amnesia for Antisocial Behavior scale with Fs in step two, RBS in step three, and FBS-r 
in step four 
Variable R Z?2 AdjR2 R2change F(change) df change sig 
Step 1 
Demographics .370 .137 .082 .137 2.49 (4, 63) .052 
Step 2 
Fs .419 .175 .109 .039 2.92 (5, 62) .093 
Step 3 
RBS .430 .185 .105 .010 .72 (6, 61) .398 
Step 4 
FBS-r .451 .203 .110 .018 1.36 (7,60) .248 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
Prediction of ability test performance on the Repeatable Battery for the Assessment of 
Neuropsychological Status (RBANS) by MMPI-2-RF Fs, FBS-r, and RBS, controlling for 
demographic characteristics 
To address question #4, scores on the RBANS substantive scales were compared 
by dividing the sample into participants identified as over-reporting on at least one 
MMPI-2-RF validity scale versus valid respondents. A moderate effect size was 
observed between groups on the RBANS Delayed Memory Index. Those who failed at 
least at least one MMPI-2-RF over-reporting scale compared to those produced valid 
results tended to perform more poorly than those who did not fail at least one MMPI-2-
RF over-reporting scale (Table 63). 
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Table 63 
Mean and standard deviations on RBANS based on MMPI-2-RF over-reporting scales 
pass/fail classification status 
RBANS scale MMPI-2-RF valid 
M ( S D )  
MMPI-2-RF invalid 
M ( S D )  
Cohen's d 
Immediate Memory 84.05(15.71) 83.47 (15.79) 0.03 
Delayed Memory 87.68 (14.95) 78.88 (13.38) 0.62 
Visuospatial/Const. 86.90(17.26) 82.18(19.73) 0.25 
Language 91.10(11.04) 87.05 (12.18) 0.35 
Attention 86.47 (16.61) 87.06(19.94) 0.03 
Note. RBANS: Repeatable Battery for the Assessment of Neuropsychological Status. 
•Significant at the 0.05 level 
Pearson correlations were also conducted to examine the relationship among 
continuous results (Table 64). Moderate, negative relationships were observed among 
RBS, FBS-r, and Fs in comparison to the Delayed Memory subtest. This suggests that as 
scores on the Delayed Memory subtest decreased, items on each MMPI-2-RF scale were 
endorsed more frequently. RBS also demonstrated moderate, negative relationships with 
the Immediate Memory, Visuospatial/Constructional, and Language subtests. 
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Table 64 
Linear correlations between Green's MSVT scales and the MMPI-2-RF over-reporting 
scales 
RBANS subtests RBS FBS-r Fs 
Immediate Memory -.31* -.13 -.14 
Delayed Memory -.46** -.29** -.30** 
Visuospatial/Constructional -.24* -.25* -.20 
Language -.28** -.21 -.17 
Attention -.22 -.11 -.01 
Note. RBANS: Repeatable Battery for the Assessment of Neuropsychological Status; RBS: Response Bias 
Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms Scale. 
* Significant at the .05 level 
^^Significant at the .01 level 
Hierarchical linear regression analyses were used to predict performance on the 
RBANS individual subtests, including immediate and delayed memory, 
visuospatial/constructional skills, language, and attention. As in the previous linear 
regression analyses, the independent variables were entered in four blocks. Demographic 
variables were entered in the model in the first block to determine their influence in the 
model, followed by the MMPI-2-RF over-reporting variables. The order was varied until 
each option was exhausted in these analyses to determine the predictive value of each 
scale. 
On the RBANS Immediate Memory Index, demographic variables significant 
predicted 16% of the variance, Z?2 = .21, F (4,72) = 4.66, p < .01 (Table 65). Additional 
hierarchical regression analyses revealed that ethnicity accounted for a significant portion 
of the variance when entered in the first step, though none of the other demographic 
characteristics added significantly to the model, R2 = .21, F (4,72) = 4.66, p < .01. In 
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addition, RBS explained an additional 11% of the variance when entered in step two. Fs 
and FBS-r did not add significant incremental validity to this model and RBS 
significantly predicted performance on this measures, regardless of when each scale was 
entered into the model (Tables 66,67,68). Variance inflation factors raised no significant 
concerns about multicollinearity. Independence of errors was also found, Durbin 
Watson Test = 2.42. The assumptions of homoscedasticity and normality of residuals 
were also met through inspection of a scatterplot, histogram, and p-p plot. 
Table 65 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and RBANS 
Immediate Memory Index 
Variable R /f2 AdjR2 R2change F(change) df change sig 
Step 1 
Demographics .396 .157 .109 .114 3.31 (4,71) .015 
Step 2 
RBS .520 .271 .219 .114 6.30 (5,71) .014 
Step 3 
Fs .521 .271 .209 .001 .001 (6, 70) .795 
Step 4 
FBS-r .521 .198 .198 .000 .000 (7, 69) .887 




Hierarchical regression analysis of the MMP1-2-RF over-reporting scales and RBANS 
Immediate Memory Index with FBS-r in step two, RBS in step three, and Fs in step four 
Variable R /f2 AdjR2 R2change /•"(change) df change sig 
Step 1 
Demographics .396 .157 .109 .157 3.31 (4,71) .015 
Step 2 
FBS-r .435 .189 .131 .032 2.75 (5,70) .102 
Step 3 
RBS .484 .234 .168 .045 4.08 (6,69) .047 
Step 4 
Fs .487 .237 .158 .003 .238 (7,68) .627 
Note. RBS: Response Bias Scale; FBS-r: 
Scale. 
Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Table 67 
Hierarchical regression analysis of the MMP1-2-RF over-reporting scales and RBANS 
Immediate Memory Index with Fs in step two, RBS in step three, and FBS-r in step four 
Variable R R? AdjR2 R2change F(change) df change sig 
Step 1 
Demographics .396 .157 .109 .157 3.31 (4,71) .015 
Step 2 
Fs .415 .172 .113 .015 1.28 (5,70) .262 
Step 3 
RBS .485 .235 .169 .063 5.72 (6,69) .020 
Step 4 
FBS-r .487 .237 .158 .001 .126 (7,68) .723 




Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and RBANS 
Immediate Memory Index with Fs in step two, FBS-r in step three, and RBS in step four 
Variable R AdjR2 R2 change /""(change) df change sig 
Step 1 
Demographics .396 .157 .109 .157 3.31 (4,71) .015 
Step 2 
Fs .415 .172 .113 .015 1.28 (5,70) .262 
Step 3 
FBS-r .436 .190 .120 .018 1.54 (6,69) .219 
Step 4 
RBS .487 .237 .158 .047 4.16 (7,68) .045 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
On the RBANS Delayed Memory Index, RBS accounted for an additional 18% of 
the variance after demographic variables were accounted for when entered in step two 
(Table 69). When FBS-r and Fs were entered in step two, each significantly predicted 
performance on the Delayed Memory Index, though RBS consistently added incremental 
validity when it was included after these scales (Tables 70,71,72). Each scale 
demonstrated significant predictive validity, though not above and beyond what was 
explained by RBS. 
Fs and FBS-r did not add significant predictive validity to this model. Variance 
inflation factors raised no significant concerns about multicollinearity. Independence of 
errors was also found, Durbin Watson Test = 2.26. Homoschedasticity and normality of 
residuals were demonstrated through inspection of a scatterplot, histogram, and p-p plot. 
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Table 69 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and RBANS 
Delayed Memory Index 
Variable R R2 AdjR2 R2change F(change) df change sig 
Step 1 
Demographics .219 .048 -.006 .141 .90 (4,71) .470 
Step 2 
RBS .478 .229 .175 .181 19.47 (5,71) .000 
Step 3 
Fs .480 .231 .165 .002 .154 (6, 70) .696 
Step 4 
FBS-r .484 .234 .156 .003 .290 (7, 69) .592 
Note. RBS: Response Bias Scale; FBS-r: 
Scale. 
Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Table 70 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and RBANS 
Delayed Memory Index with FBS-r in step two, RBS in step three, and Fs in step four 
Variable R Z?2 AdjR2 R2change F(change) df change sig 
Step 1 
Demographics .219 .048 -.006 .048 .90 (4,71) .470 
Step 2 
FBS-r .405 .164 .105 .116 9.73 (5,70) .003 
Step 3 
RBS .510 .260 .195 .095 8.90 (6,69) .004 
Step 4 
Fs .510 .260 .184 .000 .003 (7, 68) .954 




Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and RBANS 
Delayed Memory Index with Fs in step two, RBS in step three, and FBS-r in step four 
Variable R R2 AdjR2 R2change F(change) df change sig 
Step 1 
Demographics .219 .048 -.006 .048 .90 (4,71) .470 
Step 2 
Fs .359 .129 .067 .081 6.50 (5,70) .013 
Step 3 
RBS .501 .251 .185 .122 11.19 (6,69) .001 
Step 4 
FBS-r .510 .260 .184 .009 .855 (7,68) .358 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
Table 72 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and RBANS 
Delayed Memory Index with Fs in step two, FBS-r in step three, and RBS in step four 
Variable R R2 AdjR2 R2 change F(change) df change sig 
Step 1 
Demographics .219 .048 -.006 .048 .90 (4,71) .470 
Step 2 
Fs .359 .129 .067 .081 6.50 (5,70) .013 
Step 3 
FBS-r .425 .180 .109 .051 4.33 (6,69) .041 
Step 4 
RBS .510 .260 .184 .079 7.30 (7,68) .009 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
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With respect to the Visuospatial/Constructional Index of the RBANS, only FBS-r 
provided a significant contribution to the model, though only when entered prior to RBS. 
Once RBS was included, no scales significantly predicted variance in this measure after 
accounting for demographic variables (Tables 73, 74,75, and 76). Variance inflation 
factors raised no significant concerns about multicollinearity. Independence of errors 
was also found, Durbin Watson Test = 1.95. The assumptions of homoscedasticity and 
normality of residuals were also met through inspection of a scatterplot, histogram, and 
p-p plot. 
Table 73 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and RBANS 
Visuospatial/Constructional Index with RBS in step two, Fs in step three, and FBS-r in 
step four 
Variable R AdjR2 R2 change /•'(change) df change sig 
Step 1 
Demographics .228 .052 -.001 .052 .989 (4,72) .419 
Step 2 
RBS .303 .092 .028 .039 3.09 (5,71) .083 
Step 3 
Fs .318 .101 .024 .009 .009 (6,70) .393 
Step 4 
FBS-r .346 .120 .031 .019 .019 (7,69) .228 




Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and RBANS 
Visuospatial/Constructional Index with FBS-r in step two, RBS in step three, and Fs in 
step four 
Variable R R2 AdjR2 R2change F(change) df change sig 
Step 1 
Demographics .228 .052 -.001 .052 .989 (4, 72) .419 
Step 2 
FBS-r .454 .206 .149 .152 6.61 (5,70) .012 
Step 3 
RBS .454 .206 .137 .001 .05 (6, 69) .813 
Step 4 
Fs .455 .207 .125 .000 .031 (7, 68) .862 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
Table 75 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and RBANS 
Visuospatial/Constructional Index with Fs in step two, RBS in step three, and FBS-r in 
step four 
Variable R /f2 AdjR? R2change F(change) df change sig 
Step 1 
Demographics .228 .052 -.001 .052 .989 (4, 72) .419 
Step 2 
Fs .397 .158 .098 .106 2.25 (5, 70) .138 
Step 3 
RBS .410 .168 .096 .010 .86 (6, 69) .355 
Step 4 
FBS-r .455 .207 .125 .039 3.30 (7, 68) .074 




Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and RBANS 
Visuospatial/Constructional Index with Fs in step two, FBS-r in step three, and RBS in 
step four 
Variable R R2 AdjR2 ft2change F(change) df change sig 
Step 1 
Demographics .228 .052 -.001 .052 .989 (4, 72) .419 
Step 2 
Fs .397 .158 .098 .106 2.25 (5, 70) .138 
Step 3 
FBS-r .455 .207 .138 .049 4.23 (6,69) .043 
Step 4 
RBS .455 .207 .125 .000 .02 (7, 68) .883 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
With respect to performance on the Language Index, RBS predicted significantly 
more variance than demographic variables only when entered in step two, though this 
was not significant in terms of the overall model (Tables 77, 78,79, and 80). Variance 
inflation factors raised no significant concerns about multicollinearity. Independence of 
errors was also found, Durbin Watson Test = 1.88. Homoscedasticity and normality of 
residuals were demonstrated through inspection of a scatterplot, histogram, and p-p plot. 
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Table 77 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and RBANS 
Language Index 
Variable R R2 AdjR2 /f2 change F(change) df change sig 
Step 1 
Demographics .271 .073 .022 .073 1.42 (4, 72) .235 
Step 2 
RBS .365 .133 .072 .060 4.91 (5,71) .030 
Step 3 
Fs .369 .136 .062 .003 .248 (6, 70) .620 
Step 4 
FBS-r .370 .137 .049 .000 .026 (7, 69) .872 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
Table 78 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and RBANS 
Language Index with FBS-r in step two, RBS in step three, and Fs in step four 
Variable R R2 AdjR2 R2change F(change) df change sig 
Step 1 
Demographics .271 .073 .022 .073 1.42 (4,71) .235 
Step 2 
FBS-r .352 .124 .061 .051 3.33 (5, 70) .072 
Step 3 
RBS .395 .156 .082 .032 2.63 (6, 69) .109 
Step 4 
Fs .398 .158 .072 .002 .19 (7, 68) .662 




Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and RBANS 
Language Index with FBS-r in step two, RBS in step three, and Fs in step four 
Variable R R2 AdjR2 R2change F(change) df change sig 
Step 1 
Demographics .271 .073 .022 .073 1.42 (4,71) .235 
Step 2 
Fs .352 .124 .061 .042 3.32 (5, 70) .073 
Step 3 
RBS .395 .156 .082 .032 2.63 (6, 69) .109 
Step 4 
FBS-r .398 .158 .072 .002 .19 (7, 68) .662 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
Table 80 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and RBANS 
Language Index with Fs in step two, FBS-r in step three, and RBS in step four 
Variable R R2 AdjR2 R2change F(change) df change sig 
Step 1 
Demographics .271 .073 .022 .073 1.42 (4,71) .235 
Step 2 
Fs .352 .124 .061 .042 3.32 (5, 70) .073 
Step 3 
FBS-r .370 .137 .062 .013 1.06 (6, 69) .306 
Step 4 
RBS .398 .158 .072 .021 1.72 (7, 68) .194 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
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Finally, none of the MMPI-2-RF over-reporting measures predicted a significant 
amount of variance on the RBANS Attention Index when entered at varying stages in the 
model (Tables 81, 82, 83, and 84). Variance inflation factors raised no significant 
concerns about multicollinearity. Independence of errors was also found, Durbin Watson 
Test = 1.57. The assumptions of homoscedasticity and normality of residuals were also 
met through inspection of a scatterplot, histogram, and p-p plot. 
Table 81 
Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and RBANS 
Attention Index 
Variable R /i!2 AdjR2 R2change /•"(change) df change sig 
Step 1 
Demographics .189 .036 -.019 .053 .65 (4, 72) .631 
Step 2 
RBS .383 .080 .014 .056 2.05 (5,71) .157 
Step 3 
Fs .305 .093 .014 .013 .01 (6, 70) .322 
Step 4 
FBS-r .305 .093 .000 .000 .00 (7, 69) .974 




Hierarchical regression analysis of the MMP1-2-RF over-reporting scales and RBANS 
Attention Index with FBS-r in step two, RBS in step three, and Fs in step four 
Variable R AdjR2 R2 change F(change) df change sig 
Step 1 
Demographics .189 .036 -.019 .053 .65 (4,72) .631 
Step 2 
FBS-r .200 .040 -.030 .004 .31 (5,70) .578 
Step 3 
RBS .255 .065 -.018 .025 1.82 (6,69) .182 
Step 4 
Fs .282 .079 -.017 .014 1.05 (7,68) .309 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
Table 83 
Hierarchical regression analysis of the MMP1-2-RF over-reporting scales and RBANS 
Attention Index with Fs in step two, RBS in step three, and FBS-r in step four 
Variable R R? AdjR2 R2 change F(change) df change sig 
Step 1 
Demographics .189 .036 -.019 .053 .65 (4,72) .631 
Step 2 
Fs .189 .036 -.034 .000 .00 (5,70) .948 
Step 3 
RBS .282 .079 -.002 .044 3.23 (6,69) .077 
Step 4 
FBS-r .282 .079 -.017 .000 .00 (7,68) .989 




Hierarchical regression analysis of the MMPI-2-RF over-reporting scales and RBANS 
Attention Index with Fs in step two, FBS-r in step three, and RBS in step four 
Variable R R2 AdjR2 R2 change F(change) df change sig 
Step 1 
Demographics .189 .036 -.019 .053 .65 (4,72) .631 
Step 2 
Fs .189 .036 -.034 .000 .00 (5,70) .948 
Step 3 
FBS-r .205 .042 -.042 .007 .47 (6,69) .497 
Step 4 
RBS .282 .079 -.017 .037 2.71 (7,68) .105 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale. 
Sensitivity, specificity, positive predictive power, and negative predictive power of the 
MMPI-2-RF over-reporting scales in relation to SVTperformance 
To address question #4, Hit Rate, Sensitivity, Specificity, Positive Predictive 
Power, and Negative Predictive Power were calculated at varying cutoff scores (Table 
85). However, given the small sample size, these results are provided as proposed, but 
should not be considered as clinical guidelines. Sensitivity denotes the proportion of 
individuals who demonstrated negative response bias (via MSVT failure) who were 
identified by the MMPI-2-RF over-reporting scales while specificity refers to those who 
did not demonstrate negative response bias (via MSVT pass) who were identified as 
having produced valid results on the MMPI-2-RF over-reporting scales. 
When analyses were performed, optimal hit rates were achieved for FBS-r by T 
scores >110 with a hit rate of .79, though it is important to mention that no participants 
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produced invalid results on both FBS-r and the MSVT, thus limiting the generalizability 
of this data. The highest hit rate for RBS was achieved at T > 80, though the sensitivity 
of the measure suffered as a result. Based on this data, it appeared as though the optimal 
cutting score was T > 100, as currently recommended for interpretation. Similarly, Fs 
achieved the strongest hit rate when a T > 90 was implemented. The measure's 
sensitivity was negatively affected here, also. The current recommended cutting score of 
T > 99 produced the best rates for sensitivity and specificity. 
A review of negative predictive power (NPP) results and crosstabulation 
frequencies revealed that no patients failed both the MSVT and FBS-r at any of the 
implemented cut-scores. Subsequently, recommendations for FBS-r based on NPP will 
not be made. With respect to RBS, three patients produced invalid results on both the 
MSVT and RBS when the recommended cutting score of 99 was used, demonstrating an 
NPP of .75. Twelve out of the 63 patients (19%) who scored below a T score of 100 on 
RBS produced invalid results on the MSVT. When the threshold was lowered to T scores 
of 90 and 80, NPP fell to .44 and .31, respectively. 
With respect to Fs, only one participant scored above the recommended cutting 
score of 99 and also produced an invalid profile on the MSVT, thus producing a NPP of 
.08. Of the 58 patients who scored below a T score of 99 on Fs, 14 patients (24%) 
invalidated the MSVT. When the threshold was lowered to a T score of 90,45 
participants scored below this score. Of these, 10 participants performed in the invalid 
range on the MSVT, thus demonstrating a NPP of .27. Lowering the T score threshold to 
80 did not improve this rate, as NPP was calculated to be .21. 
The MMPI-2-RF over-reporting scales produced good positive predictive power 
(PPP) at different cutting scores. When the recommended cutting T score of 99 was used 
for Fs, a PPP rate of .76 was demonstrated. However, PPP improved to .81 when the 
threshold was lowered to T > 90. Positive predictive power did not increase when the 
threshold was raised above the recommended cutting score. Similarly, RBS 
demonstrated its strongest PPP at T > 80. Increasing the threshold required for an invalid 
result subsequently decreased PPP. Finally, FBS-r demonstrated relatively consistent 
rates of PPP, likely due to the fact that no participant produced invalid results on both the 
MSVT and FBS-r at any threshold utilized. 
Table 85 
Hit rates, sensitivity, specificity, positive predictive power, and negative predictive power 
for the FBS-r, Fs, and RBS scales at varying cut scores 
MMP1-2-RF Scale Cut Scores Hit Rate Sensitivity PPP Specificity NPP 
FBS-r T> 80 .77 .53 .77 .74 0 
r>90 .77 1.00 .77 .93 0 
T> 99 .78 1.00 .78 .97 0 
T> 105 .78 1.00 .78 .99 0 
T> 110 .79 1.00 .79 1.00 0 
Fs T> 80 .78 .67 .78 .68 .20 
T> 90 .81 .80 .81 .86 .27 
T> 99 .76 .93 .76 .89 .08 
T> 105 .76 .95 .79 .94 0 
7"> 110 .76 1.00 .79 .96 0 
RBS T> 80 .88 .27 .88 .97 .31 
r>90 .87 .47 .87 .97 .44 
T> 100 .81 .80 .81 .93 .75 
T> 105 .75 .97 .75 .97 0 
T> 110 .78 1.00 .78 1.00 0 
Note. RBS: Response Bias Scale; FBS-r: Fake Bad Scale—Revised; Fs: Infrequent Somatic Symptoms 
Scale; PPP = positive predictive power; NPP = negative predictive power. 
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DISCUSSION 
The current study was designed to expand the knowledge base surrounding the 
efficacy and utility of the MMPI-2-RF in clinical neuropsychological settings. Recent 
statements from the American Academy of Clinical Psychology and the National 
Academy of Neuropsychology have called for use of embedded and stand-alone validity 
measures to assess cognitive effort and symptom exaggeration over the course of a 
neuropsychological battery, especially when involved in forensic evaluation. Since the 
MMPI-2-RF is a relatively new measure, it is important to explore the reliability and 
validity of scales on this measure with other instruments or measures that have 
established research bases. Results of this study would contribute to the assessment of 
symptom validity in clinical neuropsychology. 
A limitation of some past research on symptom exaggeration has been the reliance 
on feigned symptom exaggeration. Gervais and colleagues have conducted multiple 
studies in true patient samples. This present research sought to expand on this literature in 
a meaningful way by exploring data from actual patients from a private neuropsychology 
practice. It was hypothesized that elevated scores on the RBS, FBS-r, and Fs would be 
associated with reduced performance on a cognitive symptom validity test (Green's 
MSVT) and a cognitive ability screening measure (RBANS), in addition to increased 
subjective memory complaints. Sensitivity, specificity, positive predictive power, and 
negative predictive power for RBS, FBS-r, and Fs were also explored. 
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MMPI-2-RF scales and symptom validity testing 
Findings of the current study provide evidence for the utility of RBS over the 
FBS-r and Fs in predicting symptom validity test failure. However, this study is limited 
by the small number of participants who produced any elevations on over-reporting 
scales. When the validity scale scores were compared between the groups who produced 
valid results on the MSVT versus those who did not, a large effect was observed for RBS 
(0.88) and a medium effect was noted for FBS-r (0.62), but only a small effect was 
indicated for Fs (0.10). As expected, the group who failed the MSVT scored higher on 
RBS than the group who passed the MSVT and consequently demonstrated a large effect 
size. Regression analyses showed that RBS accounted for the most variance on all 
MSVT scales when entered in step two after accounting for demographic variables with 
statistically significant contributions each MSVT scale. The addition of Fs and FBS-r did 
not add incrementally to the RBS in predicting MSVT performance when RBS was 
entered in step two. However, FBS-r significantly predicted performance when entered 
prior to RBS on the MSVT Delayed Recall, Paired Associates, and Consistency Index. 
The RBS still provided incremental validity above and beyond that explained by FBS-r 
and Fs on each MSVT subtest, though not on the Consistency Index. A series of binary 
logistic regressions revealed that RBS provided significant contribution in determining 
whether or not a patient passed or failed the MSVT. Pearson correlations demonstrated 
statistically significant mild to moderate positive relationships between RBS and all 
MSVT scales. Correlational analyses from FBS-r indicated mild positive relationships 
with the Delayed Recall and Paired Associates trials of the MSVT, though comparisons 
with Fs did not reflect any statistically meaningful relationships. 
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This data aligns with past research and development of the RBS. Most recently, 
Gervais, Wygant, Sellbom, and Ben-Porath (2012) demonstrated a significant association 
between symptom validity test failure and elevated scores on the MMPI-2-RF validity 
and substantive scales. While FBS-r significantly predicted performance on portions of 
the MSVT, the RBS consistently outperformed Fs and FBS-r in this study, as Fs and 
FBS-r did not add significant incremental explanation above and beyond what was 
explained by RBS, with the exception of the Consistency Index. Similar results were 
found in the initial validation research with RBS, such that RBS reliably predicted 
performance on four symptom validity measures above and beyond what was predicted 
by the F-family of the MMPI-2 (Gervais et al., 2007). 
The findings for Fs and FBS-r support past research that demonstrates the 
superiority of RBS in detecting symptom validity test failure. While FBS-r did provide 
significant predictive utility for performance on the MSVT, it did not contribute 
significantly when RBS was entered into the model prior to entering FBS-r. This may 
reflect its development as a measure of neurocognitive and somatic symptom validity, 
though findings are still surprising, given that many patients in the sample presented with 
at least comorbid pain-related issues; however, measures were included that assessed 
cognitive complaints and objective deficits rather than exaggerated pain or physical 
complaints. It is likely that results on Fs and FBS-r may have demonstrated significant 
relationships with symptom validity measures that assessed exaggerated somatic 
symptoms (Ben-Porath, 2012), though none were incorporated in the design of this study. 
These findings may have also been affected by the small sample size and, subsequently, 
the small number of patients who were classified as over-reporting on FBS-r based on T 
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> 99 criteria likely contributed to this underwhelming finding. Future research should 
examine this scale in a sample where Fs and FBS-r are more frequently elevated in 
relation to measures of exaggerated somatic symptoms. 
MMPI-2-RF scales and subjective memory complaints 
It was proposed that performance on RBS, FBS-r, and Fs would predict subjective 
memory complaints. Linear regression analyses indicated that RBS independently 
predicted performance on MCI scales, including general memory problems, numerical 
information problems, visuospatial memory problems, verbal memory problems, memory 
interferes with work, impairment in remote memory, and amnesia for complex behavior. 
However, once again, FBS-r also significantly predicted performance on these measures 
when entered before RBS. The RBS still provided incremental validity above and 
beyond what was explained by FBS-r when entered after FBS-r. Furthermore, FBS-r 
significantly predicted increased scores on scales assessing pain that interferes with 
memory and amnesia for antisocial behavior. Neither RBS nor Fs provided significant 
predictive utility on these measures, even when the order of entry into the model was 
varied. Fs did not provide significant incremental validity on any of the scales of the 
MCI. Overall, RBS predicted performance on functional aspects of subjective memory 
aimed at different cognitive domains while FBS-r independently predicted performance 
on a somatic pain scale. 
These findings are consistent with the goals of scale development for both the 
RBS and FBS-r. Based on this data, RBS and FBS-r are related to subjective memory 
complaint scales that are similar in content. It appears that those who exaggerate 
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memory difficulties on the MCI may tend to respond to items with similar content on the 
MMPI-2-RF and may subsequently increase respective scores on RBS or FBS-r. Pearson 
correlations demonstrated significant, positive correlations between RBS and scales 
assessing probable and improbable memory complaints. Similarly, FBS-r also showed 
significant positive correlations that were small to moderate in strength while 
performance on Fs indicated significant positive correlations that were small in strength. 
It is important to note that correlations observed on the improbable complaints scales of 
the MCI may be attributed to range restriction, as there are few items on these scales that 
have a generally low rate of endorsement. These correlation analyses align with the 
findings of Gervais et al. (2010) who found that RBS demonstrated the strongest 
relationship with mean memory complaints. Findings from the 2010 study reflect the 
incremental validity provided by RBS in identifying exaggerated subjective memory 
complaints while demonstrating little to no relationship with objective memory 
dysfunction, after controlling for symptom validity test results. 
MMPI-2-RF scales and performance on the RBANS 
Few studies to date have examined performance on embedded and stand-alone 
symptom validity measures in comparison to performance on tests of cognitive ability. 
Recently, Armistead-Jehle, Gervais, and Green (2012) examined subjective memory 
complaints compared to objective memory data and found that as performance on various 
symptom validity tests worsened, there was an increase in subjective memory complaints. 
Furthermore, non-significant correlations were found between subjective memory 
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complaints and performance on objective memory measures for those who passed 
symptoms validity measures in the same study. 
In this study, it was hypothesized that as scores on the MMPI-2-RF over-reporting 
scales increased, performance on a cognitive abilities screening measure would decrease. 
Pearson correlations revealed significant negative relationships between the performance 
on the Delayed Memory scale of the RBANS and RBS, FBS-r, and Fs. Small to 
moderate negative relationships were observed between RBS and performance on tasks 
assessing immediate working memory, visuospatial/constructional ability, and language. 
Results from regression analyses indicated that RBS independently predicted 
performance on the Immediate and Delayed Memory Indexes but did not significantly 
predict performance on other indexes assessing language, attention, and visuospatial and 
constructional skills. Both FBS-r and Fs also significantly predicted delayed memory 
performance, though only when entered prior to RBS. Based on these data, it appears 
there is a significant relationship among worsening performance on measures assessing 
patients' ability to retain novel information both immediately and following a delay for 
those who produced elevated scores on RBS. This finding supports the hypothesis that 
ability test scores are reduced as over-reporting increases, though it is specific to scales 
and measures similar in content. The RBS has been demonstrated to be specifically 
associated with subjective memory complaints (Ben-Porath, 2012). Therefore, it makes 
sense that it would provide predictive utility on objective measures of immediate and 
delayed memory. 
While FBS-r and Fs did not provide incremental validity beyond RBS in detecting 
memory performance, it is important to emphasize that these measures may also serve as 
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useful tools that clinicians may use to provide further evidence when determining 
whether or not a patient is exaggerating symptoms, especially as it pertains to memory 
complaints. These scales provided significant prediction above and beyond demographic 
variables for performance on attention, language, and visuospatial/constructional tasks, 
though these discrepancies were not significant in terms of the overall model. Additional 
research with a larger sample size is necessary to clarify this finding, though it may 
provide insight into performance across a neuropsychological test battery when 
exaggeration is suspect. 
Cutting scores for the MMPI-2-RF over-reporting scales 
Hit Rate, Sensitivity, Specificity, Positive Predictive Power and Negative 
Predictive Power were examined; however, the small sample size precluded useful 
calculation of cutoff scores. Subsequently, the values provided should inform future 
research but should not be utilized as clinical guidelines. Based on the results obtained, 
the current cutting score for RBS of T> 100 minimized false positives (specificity = .93) 
while retaining a good sensitivity of .80. These data suggest that a clinician would have 
an 81% probability of being correct in suspecting symptom exaggeration when given a 
positive finding on the RBS. The same clinician would have a 75% probability of being 
correct of suspecting a patient was not attempting to exaggerate symptoms if given 
negative findings on the RBS. Though a stronger hit rate was found for a cutting score of 
T > 80, sensitivity was negatively affected as a result. Limited data were gleaned for both 
FBS-r and Fs, as few patients produced invalid results on each scale and Green's MSVT 
at the current recommended cutting scores. When the threshold was lowered for Fs, 
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however, the hit rate and positive predictive power both increased, though negative 
predictive power still remained low. In conclusion, these scales demonstrated good 
utility in detecting symptom exaggeration; however, the sample size of this study limits 
clinical utility and future studies should evaluate current cutoff scores. 
Strengths, limitations, and future directions 
A discussion of strengths and limitations of the current study in relation to other 
research in this area may help guide future research. One advantage of the current study 
was the use of a clinical sample from a private neuropsychology practice, which 
increased the ecological validity of this study. Most symptom validity research to date 
has taken place with samples instructed to feign symptoms of neurologic, medical, and 
psychiatric disorders. The inclusion of actual patients incorporated many factors that 
may have been absent from a population instructed to feign difficulties associated with 
varying conditions. Referrals for neuropsychological evaluations typically take place 
after the patient, a treating physician, attorney, or governing body suspect cognitive 
decline. Patients' internalized responses to these deficits are variable and depend on the 
level of deficit, individual coping strategies, comorbid psychiatric, medical, or neurologic 
conditions, and social support. By including a clinical sample in this study, individual 
variations were captured that may not have been apparent in a feigned sample. 
Conversely, use of an actual patient sample introduced methodological variance 
that is typically controlled for in research settings. Patients were exposed to different 
assessment batteries depending on the referral question and assessments included in this 
study were administered at any given point in the course of the evaluation. This may 
have affected performance on these measures, as patient motivation, fatigue, and test 
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stamina could not be controlled or assessed. Furthermore, patients were grouped based 
on performance on specific validity scales when between-groups comparisons were 
made. In feigned samples, groups are known and predictive analyses leave little room for 
suspicion. Groups in this sample included those suspected of over-reporting based on 
negative bias versus accurate responding, per the cutting scores suggested in prior 
research of the respective MMPI-2-RF scales, though no definitive classification could be 
gleaned based on available data. 
The most significant limitation of this study is the sample size. Future cross-
validation research should employ a sample size of at least 100 participants who have 
been administered similar neuropsychological batteries. Larger samples would be 
desirable for calculations of Hit Rate, Sensitivity, Positive Predictive Power, and 
Negative Predictive Power. 
Another limitation is the issue of secondary gain. It is unknown if patients might 
have engaged in negative responding for reasons other than incentives arising from legal 
involvement. The sample size was too small to empirically evaluate this issue. Other 
incentives for negative responding may have been present but were not assessed and 
subsequently not incorporated into this study design. Given the findings that RBS 
predicted performance on measures with similar cognitive constructs, it would have been 
interesting to include other measures of physical exaggeration and pain complaints that 
were conceptually similar FBS-r and Fs. Future research might examine different groups 
based on the type of complaints presented, such as pain-related disability and a more 
specific somatic response bias in comparison to those who present primarily cognitive 
deficits. Findings from this study may provide insight to different types of symptom 
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exaggeration in a neuropsychological setting to determine what neuropsychological 
correlates exist in those feigning somatic complaints in comparison to other types of 
exaggerated presentations. Since the MMPI-2-RF is still a relatively new clinical 
assessment tool, further research is still necessary to investigate relationships among 
different types of symptom validity tests and the validity scales of the MMPI-2-RF. 
While the current findings support the use of RBS and its superiority in comparison to 
other over-reporting scales in detecting cognitive malingering, other validity scales may 
aid in detecting psychiatric or somatic symptom exaggeration. 
The test selection procedure that took place when developing the subject database 
may also be considered a limitation of the study. During a review of individual test 
batteries, participants were chosen who had been administered Green's MSVT, Green's 
MCI, and the RBANS as part of a neuropsychological evaluation. These tests were 
chosen based on their assessment constructs in addition to their frequency in which they 
were utilized. In practice, neuropsychologists typically choose flexible test batteries that 
are adapted to referral questions and concerns discussed in an initial clinical interview 
with the neuropsychologist. Patients who were administered batteries that included these 
specific tests may have fit a symptom profile at the time of intake. It could be that 
symptom exaggeration was suspected upon the first meeting, thus introducing a potential 
selection bias with patients administered tests to detect symptom exaggeration, purely 
based on what patients were administered which measures. Chart reviews revealed 
diverse presentations and background information; therefore, no motivations were 
apparent for test selection among these patients and an equal mix of litigating versus non-
litigating patients was included in this study. 
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Furthermore, while use of the RBANS provided interesting insight regarding the 
relationship between RBS and performance on memory measures, it has historically been 
used as a screen for impairment to subsequently conduct further testing in areas of 
concern. Future research between the MMPI-2-RF over-reporting scales and 
performance on ability measures should include a more in-depth assessment, such as the 
Weschler Memory Scale—Fourth Edition or the Wide Range Assessment of Memory and 
Learning. These assessments would allow for further exploration of the role of these 
scales in predicting performance on visual and verbal memory tasks, in addition to 
attention, concentration, and recognition as a function of overall memory performance. 
Summary and clinical implications 
The current study found RBS was predictive of pass/fail classification status on a 
cognitive symptom validity test, subjective memory complaints that pertained to 
cognitive functioning, and performance on immediate and delayed memory measures. 
The FBS-r provided significant predictive utility on these measures also, though not 
above and beyond what was explained by RBS to a statistically significant degree. 
However, the study was underpowered to detect small effects. The FBS-r tended to 
predict increased scores on Green's MCI that pertained to pain complaints and memory. 
The Fs scale significantly predicted performance on Green's MCI Memory Interferes 
with Work and Amnesia for Complex Behavior scales but Fs did not provide incremental 
validity above and beyond RBS for any of the measures employed in this study. This 
may have been attributed to the use of measures that assessed cognitive functioning 
rather than somatic complaints or pain exaggeration. Furthermore, RBS, FBS-r and Fs 
demonstrated good utility in predicting delayed memory performance on a brief 
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neurocognitive screening measure, though here too, RBS had superior results in 
comparison to FBS-r and Fs. 
The results of the current study support the utility of RBS as part of a 
neuropsychological assessment, as it appears to detect symptom exaggeration and 
cognitive response bias on both objective and subjective measures that subsequently 
influence performance on neuropsychological testing of memory functioning. The utility 
of FBS-r was also demonstrated in these data and it should be included as a supplement 
to RBS when considering symptom exaggeration in patients. Furthermore, these scales 
may provide insight into performance on objective measures of memory. Based on the 
relatively recent implementation of the MMPI-2-RF and even more recent inclusion of 
RBS in the scoring program, it is recommended that those new to this measure become 
familiar with this scale's development and its contribution to various clinical 
interpretations. 
Although the RBS was superior to the FBS-r and Fs in this sample in detecting 
cognitive symptom exaggeration, it is important to emphasize that it should not be used 
in isolation and that other scales of the MMPI-2-RF, measures of validity, and clinical 
judgment should be employed when there is a question of effort. Slick and colleagues 
recommended routine use of at least two well-validated symptom validity assessments as 
a core of neuropsychological assessment (1999). In this study, there was no difference in 
performance for those with pending litigation and those who did not have apparent 
secondary gain. It is subsequently recommended that symptom validity testing tailored to 
specific symptom complaints (e.g., somatic, cognitive, etc.) be utilized in all adult 
neuropsychological batteries, especially when there is a potential benefit for reduced 
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performance. It should be noted, however, that the potential for false positive error rates 
increases with the use of multiple symptom validity tests. To minimize this potential, 
clinicians should utilize several well-validated symptom validity measures, which will 
also aid in reducing the false-negative rate. 
engage in a thorough review of all objective data, the clinical interview, 
behavioral observations, and collateral information gleaned from other sources prior to 
assuming the patient engaged in volitional symptom exaggeration. If an external 
incentive is absent, DSM-IV-TR factitious or somatization disorders must be considered, 
as over-reporting in isolation is not indicative of malingering (Ben-Porath, 2012). 
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